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ABSTRACT 
 
GRETCHEN MARIE SPROW: The Role the Melanocortin System 
in Binge-Like Ethanol Consumption 
(Under the direction of Todd E. Thiele) 
The melanocortin system has a well-established role in modulating feeding behavior 
and energy homeostasis. Recent data has also indicated that this system modulates some 
neurobiological responses to ethanol. The goal of this dissertation was to explore the role of 
the melanocortin system in binge-like ethanol intake, a destructive pattern of ethanol 
consumption that is linked with the development of dependence in the human population. In 
Chapter 2, the effect of repeated cycles of binge-like ethanol intake on key components of the 
melanocortin system was measured using immunohistochemical techniques. In agreement 
with previous literature, it was observed that excessive ethanol intake is associated with a 
downregulation of an endogenous melanocortin agonist and an upregulation of an 
endogenous melanocortin antagonist. As the most robust changes were observed in the lateral 
hypothalamus (LH), Chapter 3 sought to determine whether site-directed pharmacological 
manipulation of the melanocortin-4 receptor (MC4R), believed to be the most important 
melanocortin receptor involved in modulating ethanol-related behaviors, in this region would 
be sufficient to modulate binge-like ethanol intake. To this end, it was shown that intra-LH 
agonism blunted, while intra-LH antagonism augmented, binge-like ethanol intake. To date, 
the intracellular signaling mechanisms activated by agonism at the MC4R are not completely 
understood. In Chapter 4, we sought to determine whether the blunting of ethanol intake 
induced by intra-LH melanocortin agonism required signaling through the extracellular 
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signal-related kinase (ERK) pathway. Here, it was shown that intra-LH pre-treatment with an 
inhibitor of this pathway blunted the expected effect of a potent melanocortin agonist on 
binge-like ethanol intake, suggesting that melanocortin agonism via MC4R in the LH 
requires ERK signaling. Together, these data indicate that the melanocortin system, in 
addition to regulating feeding behavior and energy homeostasis, plays an important role in 
modulating excessive ethanol intake. Given the present data, we hypothesize that the 
melanocortin system may be an integral component of overlapping neural circuitry that may 
be involved in modulating neurobiological responses to both natural (food) and unnatural 
(drug) reinforcers.  
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 Alcohol, a natural product of fermentation, has a tumultuous story paralleling that of 
recorded human history. Alcoholic beverages, such as wine, have long been a part of human 
culture, and have at different stages been used for religious, medicinal, and recreational purposes 
(Lucia, 1972). During Prohibition (1919-1933) in the United States, the manufacture, sale, and 
transport of alcohol within the country was forbidden; throughout the relatively short duration of 
this reform movement, crime rates soared and a black market for alcohol sprang up. Although 
initially successful at reducing alcohol intake, illegal alcohol consumption began increasing in 
the late 1920s (Tyrrell, 1997). Prohibition was abolished by the Twenty-First Amendment due to 
the increasing unpopularity of the movement as well as a changing political climate related to the 
Great Depression (Levine, 1984); since that time, the manufacturing, sale, and consumption of 
alcohol has come to play a fundamental role in the livelihood of many Americans.  
 Following the repeal of the bans set forth by the Eighteenth Amendment, an abundance 
of research began to examine the role of alcohol use (and misuse) within the population. Recent 
data suggests that over 60% of the United States population (ages 18 and older) consumes at 
least one alcoholic beverage a year, with the vast majority consuming moderate or low levels of 
alcohol (no more than 7 or 14 drinks per week for a woman or man, respectively) (Schoenborn 
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and Adams, 2010). While light and perhaps moderate alcohol drinking among nondependent 
drinkers may be protective and confer a number of health benefits, alcohol consumption in 
dependent drinkers has been linked with an increase in mortality (Dawson, 2000). 
Alcoholism, characterized by increasingly persistent patterns of problematic drinking, is 
one of the leading mental disorders not only within the United States but also throughout the 
world (Goetzel et al, 2003; WHO, 2003). Further, the economic costs associated with ethanol use 
have risen to staggering levels: for example, in 2008 the hospital rates for alcohol overdoses 
alone totaled in excess of $260 million (White et al, 2011). This complex disease is characterized 
by a number of behaviors, including a preoccupation with drinking despite negative 
consequences, a loss of control over drinking, and the development of tolerance and dependence. 
Treatment of alcoholism is further complicated by the different variants of this disorder 
(delineated as Type 1 or Type 2, based on the temporal development of the disorder), as well as 
the incredible amount of comorbidity that exists with other psychiatric disorders, including 
depression, anxiety, and many personality disorders (Edwards et al, 2013; Schuckit and 
Hesselbrock, 1994). To date, despite a vast literature seeking to understand the underpinnings of 
this destructive disorder, there is a regrettable lack of pharmacological treatments available. 
Binge Alcohol Drinking 
In contrast to the considerable amount of focus on alcohol dependence in alcoholism 
research, far less attention has been paid to binge alcohol drinking, a particular pattern of 
drinking that may emerge prior to, and contribute to, the development of alcohol dependence. 
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) officially defines an alcohol 
(ethanol) binge as a pattern of drinking that produces blood ethanol concentrations (BECs) of 
3 
 
greater than 0.08% (80 mg/dl) (NIAAA, 2004). A BEC meeting this criterion typically results 
from 4-5 drinks in a 2-hour period for the average adult female or male, respectively. While 
“binge drinking” is a term commonly associated with a younger demographic, and is certainly 
quite common in college-aged individuals (Wechsler et al, 1998), this destructive pattern of 
drinking is also quite prevalent among the adult population (Nelson et al, 2009). Indeed, a 
majority of binge drinking episodes in the United States involve adults over the age of 26 (Fan et 
al, 2008a).  
Given the increasing prevalence of binge drinking, a growing literature has begun to 
examine the physiological and social consequences of this pattern of drinking. To this end, binge 
drinking has been associated with not only a decrease in general health, but also a number of 
specific health risks, including hypertension, stroke, and type 2 diabetes, among others (Fan et 
al, 2008a; Okoro et al, 2004). Additionally, binge drinking has been linked with an increased 
proclivity to participate in risky behaviors associated with potential long-term effects. For 
example, individuals who binge drink are more likely to have unprotected sex or engage in 
impaired driving (Miller et al, 2007; Naimi et al, 2003). In fact, roughly 80% of driving 
accidents attributed to alcohol are estimated to occur as a result of binge drinking (Quinlan et al, 
2005). Further, of the approximately 75,000 annual deaths resulting from excessive alcohol 
consumption within the United States, roughly half can be linked to binge drinking episodes 
(CDC, 2004). 
According to at least one source, binge alcohol drinking is also the most common pattern 
of drinking among high school students who drink (Miller et al, 2007). This is particularly 
concerning given that drinking at a young age is linked to later alcohol dependence (Grant and 
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Dawson, 1997). Additionally, binge drinking in particular appears to be a persistent pattern of 
drinking behavior, as data have shown that those who binge drink earlier in life are more likely 
to continue binge drinking into adulthood (Jefferis et al, 2005). Perhaps most alarming, binge 
drinking early in life is positively correlated with the development of alcoholism later in life 
(Hingson et al, 2006a, b; McCarty et al, 2004; Wechsler et al, 1998). By studying the 
neurobiological mechanisms that underlie binge ethanol drinking, it may be possible to tap into 
the neurocircuitry responsible for the transition to dependence, thus paving the way for 
pharmacological treatments aimed at preventing and/or alleviating this devastating disorder.  
Animal Models of Binge Drinking 
 As done for many neurological disorders, a number of animal models have been 
developed to examine individual aspects of alcohol dependence. Due to inherent species 
differences, no single rodent model can fully characterize the multi-faceted and complex 
characteristics of alcohol abuse disorders and dependence (Hines et al, 2005). For example, two-
bottle choice methods are often used to examine ethanol preference, while self-administration 
and relapse models have been used to investigate mechanisms contributing to the motivation to 
seek and consume ethanol (Spanagel, 2000). However, models such as these do not accurately 
address the defining characteristics of binge alcohol drinking. In particular, rodents used in many 
of these models do not typically consume enough alcohol (or enough alcohol over a short enough 
period of time), to generate behavioral intoxication or achieve BECs indicative of 
pharmacological intoxication (Spanagel, 2000). 
 A rodent model of binge-like ethanol drinking should fulfill certain criteria in order to 
reliably translate to humans. For example, the animal should voluntarily and orally self-
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administer ethanol to a substantial degree and over a limited time frame in order to generate a 
pharmacologically relevant BEC analogous to that specified by the NIAAA (NIAAA, 2004). 
Additionally, the ethanol should be consumed for the post-ingestive intoxicating effects, rather 
than taste or caloric fulfillment. Several currently used models fulfill some, but not all, of the 
criteria for a model of binge-like ethanol drinking. Repeated intragastric delivery of a high dose 
of ethanol has been a widely-used and validated as a technique, for example, that results in 
pharmacological and behavioral intoxication (Coleman Jr et al; Faingold, 2001). While this 
method is useful in many ways, the stressful nature of this method is perhaps not the most 
appropriate for modeling voluntary human alcohol consumption. Certain intermittent access 
protocols, including the scheduled high alcohol consumption (SHAC) model, have gained 
popularity given their ability to induce high levels of ethanol drinking (Cozzoli et al, 2009; Finn 
et al, 2005; Szumlinski et al, 2007). However, these protocols typically rely heavily on fluid 
restriction and/or lengthy induction protocols, limiting the generalizability of these protocols to 
the human condition. 
Drinking in the Dark (DID) 
  A recently developed mouse model of voluntary binge-like ethanol drinking, termed 
“Drinking in the Dark” (DID), avoids many of the problems found in other models by 
capitalizing on the innate consummatory patterns of rodents (Rhodes et al, 2005). Under this 
protocol, mice are typically presented with a bottle of 20% (v/v) ethanol three hours into the dark 
cycle; mice have access to this solution for two hours during the first three days of the DID 
cycle, with this access extended to four hours on the final “binge test” day. This protocol 
consistently yields both pharmacologically relevant BECs (greater than 80 mg/dl, and often 
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exceeding 100 mg/dl) and signs of behavioral intoxication (Rhodes et al, 2005; Rhodes et al, 
2007). Several studies have excluded thirst and caloric need as the main motivators for the high 
levels of voluntary ethanol consumption consistently observed under this protocol, suggesting 
that the high levels of intake obtained are likely due to post-ingestive effects (Lyons et al, 2008; 
Rhodes et al, 2007). To date, this protocol has been used to investigate the role of numerous 
neuromodulatory systems that may impact binge-like ethanol consumption (Sprow and Thiele, 
2012), including glutamate (Gupta et al, 2008), GABA (Melon and Boehm, 2011), the 
dopaminergic and opiodergic systems (Bulwa et al, 2011; Kamdar et al, 2007), corticotrophin 
releasing factor (CRF) (Lowery et al, 2010; Ryabinin et al, 2008; Sparta et al, 2008), and 
neuropeptide Y (NPY) (Sparrow et al, 2012). Of particular interest, one recent study also 
indicated that the melanocortin system, well known for regulating feeding behavior, may also 
regulate binge-like ethanol consumption (Navarro et al, 2008). 
The Melanocortin System 
 The melanocortin system is a well-characterized, but not completely understood, 
neuronal pathway most commonly associated with the regulation of energy homeostasis and 
feeding behavior (Cone, 2005).  The melanocortins are part of a larger peptide family, the 
melanotropins; this super-family also includes melanin-concentrating hormone (MCH), which 
serves as a functional antagonist of α-melanoctye stimulating hormone (α-MSH; see below; 
Eberle et al, 2004). Briefly, this system consists of three main components: neurons expressing 
pro-opiomelanocortin (POMC) or agouti-related protein (AgRP), the bioavailable peptides and 
proteins released from these neurons, and the receptors upon which these effectors act.   
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POMC neurons are expressed within the arcuate nucleus of the hypothalamus and to a 
lesser degree in the nucleus of the solitary tract in the brain stem (Hadley and Haskell-Luevano, 
1999). Post-translational processing of POMC yields the melanocortin agonist α-MSH, as well as 
β-MSH, γ-MSH, adrenocorticotropic hormone (ACTH), and β-endorphin (Jacobowitz and 
O'Donohue, 1978; O'Donohue and Jacobowitz, 1980; O'Donohue et al, 1979; Yeo and Heisler, 
2012). This processing is highly dependent on a number of variables, including species and 
tissue-specific prohormone convertases. These α-MSH-producing neurons, mainly originating in 
the lateral portion of the arcuate nucleus (ARC), innervate a wide distribution of regions, 
including areas of the paraventricular nucleus of the hypothalamis (PVN), the dorsomedial 
hypothalamus (DMH), the lateral hypothalamus (LH), and the preganglionic neurons of the 
spinal cord (Nahon, 2006). 
 Like POMC neurons, AgRP neurons originate in the hypothalamus. Further, AgRP is co-
expressed with neuropeptide Y (NPY), a neuropeptide with a complex involvement in both food 
(Kohno and Yada, 2012) and ethanol (Thiele et al, 2004) intake, in GABA-releasing neurons that 
largely overlap in their distribution with POMC-expressing neurons (Hahn et al, 1998). While 
AgRP has been shown to competitively antagonize signaling at both MC3R and MC4R, the 
particular physiological role of this protein is still the subject of some debate, as evidence 
suggests that AgRP might also possess inverse agonist activity at the MC4R (Haskell-Luevano 
and Monck, 2001). Although the exact nature of the relationship of this protein to the 
melanocortin system is not clear, AgRP neurons have been shown to inhibit POMC neurons via 
GABA release. Indeed, the integration of these orexigenic (AgRP/NPY) and anorexigenic 
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(melancortin, α-MSH) signals is a key regulatory factor in energy expenditure and caloric intake 
(Cowley et al, 1999; Mul et al, 2012). 
Melanocortin Receptors and Receptor Signaling Mechanisms 
The elaborate melanocortin system consists of five heterotrimeric Gs-linked G-protein 
coupled receptors (MC1R-MC5R, numbered in the order of discovery) with distinct central and 
peripheral distributions and discrete functions. These receptors differ by species, tissue 
distribution, and ligand selectivity. In general, this system has been established as modulating a 
number of behaviors, including feeding behavior, body weight and appetite regulation, 
grooming, and even anti-inflammatory responses (Chen et al, 2000; Fan et al, 1997; Gispen et al, 
1975; Macaluso et al, 1994; Mul et al, 2012; Vergoni and Bertolini, 2000). The main function of 
MC1R lies in skin pigmentation: this receptor is one of the best-characterized determinants of 
skin and hair pigmentation in both rodent and human populations (Dessinioti et al, 2011). 
MC2R, on the other hand, are present in the adrenal cortex and are also known as the 
adrenocorticotrophin (ACTH) receptors (Clark et al, 2003). The MC5R, the most recently 
discovered and also the most mysterious of the melanocortin receptor subtypes, is mainly 
expressed in exocrine glands and skeletal muscle, although it has been found in very low levels 
in several brain regions, including the cortex and striatum (Nahon, 2006). 
 MC3R and MC4R are the primary melanocortin receptors found within the brain.  While 
these receptors are colocalized in many regions, MC3R expression is somewhat more restricted, 
with the greatest distribution of this receptor found in the ARC and PVN; MC4R, on the other 
hand, are much more widely distributed throughout the CNS, with the highest expression of this 
receptor found in hypothalamic areas particularly implicated in feeding behavior, including the 
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DMH, PVN, and LH (Mountjoy et al, 1994). Both of these receptors have been strongly 
implicated the regulation of body weight and appetite regulation: central administration of the 
melanocortin agonist melanotan-II (MTII) has been shown to attenuate food intake in a dose-
dependent manner (Thiele et al, 1998), while central infusion of the melanocortin antagonist 
AgRP has been shown to increase food intake (Ebihara et al, 1999). However, converging 
evidence suggests a larger role for MC4R, relative to MC3R, in mediating many of these effects. 
Thus these receptors appear to play non-redundant roles, with the MC3R playing a stronger role 
in the regulation of energy balance (Chen et al, 2000). Deletion of the MC4R gene in a mouse 
model, on the other hand, is associated with increased food intake and weight gain (Huszar et al, 
1997). MC4R knockout mice are also irresponsive to MTII, a potent melanocortin 
‘superagonist,’ suggesting that α-MSH agonism modulates feeding behavior through MC4R, 
rather than MC3R (Marsh et al, 1999). Further, functional loss of the MC4R is the most common 
cause of human monogenic obesity, with haploinsufficiency of the MC4R accounting for up to 
3% of all cases (Calton et al, 2009; Vaisse et al, 2000). Indeed, human studies examining 
populations from several different ethnicities have indicated that mutations with this receptor in 
particular are a significant contributor to human obesity (Demiralp et al, 2011; Sull et al, 2013). 
 Despite the tremendous amount of research into the numerous behaviors impacted by this 
vast system, the intracellular signaling pathways through which melanocortin receptors exert 
their divergent effects are not completely understood. As Gs-linked G-protein coupled receptors, 
it is known that agonist binding of melanocortin receptors activates adenylyl cyclase, which in 
turn leads to an increase in cyclic AMP (cAMP); melanocortin-induced cAMP production is also 
known to increase levels of protein kinase A (PKA) activation (Gantz et al, 1993; Mul et al, 
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2012). An abundance of in vitro work has examined the role of PKA involvement in 
melanocortin actions (Ao et al, 1998); for example, activation of this cAMP-PKA pathway via 
MC4R agonism can induce expression of brain-derived neurotrophic factor (BDNF) in rat 
cultured astrocytes (Caruso et al, 2012). Further, work examining PKA activation via the RIIβ 
subunit has been shown to reduce the obesity syndrome of agouti lethal yellow mice that have a 
genetic rearrangement of the agouti locus (Czyzyk et al, 2008). More recent work has shown that 
MC4R activation within the hypothalamus, through subsequent activation of PKA, is important 
for both structural and functional synaptic plasticity: MC4R activation not only promotes 
dendritic spine maturation but also enhances surface insertion of AMPA receptors (Shen et al, 
2013) 
 In addition to the abundance of work indicating the importance of melanocortin-induced 
PKA signaling, a growing literature has found that agonism of MC3R and MC4R, as well as 
other melanocortin receptors (albeit to a lesser extent), relies on the activation of other 
intracellular mechanisms. In fact, there is some evidence to suggest that melanocortin-induced 
activation in HEK293 cells is responsive to a Gαi/0-selective inhibitor, although the possibility 
remains that this effect is cell-type specific (Chai et al, 2006). Agonism of both MC3R and 
MC4R has been shown to activate the mitogen-activated protein kinases p42 (ERK2) and p44 
(ERK1) (Chai et al, 2007; Sutton et al, 2005). Indeed, activation of the MC4R with the 
melanocortin agonist MTII dose-dependently increased phosphoryation of not only ERK1/2 but 
also cAMP response element-binding protein (CREB). Further, HEK293 cells expressing MC3R 
have also been shown to exhibit a melanocortin-induced increase in ERK1/2 phosphorylation 
(Chai et al, 2007). Additionally, melanocortin-induced PKA-mediated activation of ERK1/2 is 
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also a critical component of the α-MSH-induced desphosphorylation of AMP-activated protein 
kinase, data that suggest the PKA and ERK signaling pathways are directly linked in regards to 
at least some melanocortin-induced processes (Damm et al, 2012). 
 Melanocortin-induced activation of ERK1/2 signaling is not particularly surprising, given 
that cAMP-PKA is well known to directly influence phosphorylation of ERK1/2. However, pre-
treatment with a PKA inhibitor was unable to completely block the effect of MTII in regards to 
feeding behavior, indicating that MC4R agonism may activate ERK1/2 at least partially through 
a PKA-independent mechanism (Sutton et al, 2005).  Further, cAMP is not responsible for the 
functional coupling of MC1R to the ERK cascade (Herraiz et al, 2009), and investigation of 
MC3R signaling indicates that activation of the MC3R may (Begriche et al, 2012; Chai et al, 
2007) or may not (Daniels et al, 2003) involve ERK signaling. Further, in COS-1 cells tranfected 
with either MC3R or MC4R, it has been shown that the ERK signaling cascade is coupled 
specifically to the MC4R, but not the MC3R (Daniels et al, 2003). Additionally, at least one 
study has indicated that melanocortin-induced activation of ERK1/2 may require PKC, but not 
PKA, activity (Chai et al, 2006). Thus it remains uncertain whether melanocortin-induced 
activation of PKA and ERK1/2 belong to the same or parallel pathways (Breit et al, 2011). There 
are a number of mechanisms that may underlie this behavior, including a Gi-protein-PI3K 
signaling system or a cAMP-responsive guanine-nucleotide-exchange factor (Chai et al, 2007; de 
Rooij et al, 1998), although these possibilities have yet to be examined in depth. Clearly, further 
work is needed to clarify the mechanisms through which the melanocortin receptors exert their 
diverse effects, as the understanding of these complex mechanisms may prove beneficial in 
understanding how to manipulate these systems in order to control aberrant behavior.  
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Drugs of Abuse: Overlapping Neural Mechanisms? 
 To date, the abundance of melanocortin research has undoubtedly focused on the roll of 
this system in modulating natural physiological processes such as bodyweight and appetite 
regulation. However, a growing body of literature has indicated that this system may also play a 
role in modulating responses to drug of abuse. These data are not particularly surprising, as there 
has been a great deal of speculation regarding overlapping neural pathways underlying obesity 
and addiction (Volkow et al, 2013b). In support of this, it is well known that food can be 
consumed for purely hedonic qualities, rather than just to simply satisfy caloric needs (Hoebel 
and Teitelbaum, 1962). Further, palatable food as well as drugs of abuse both impact dopamine 
signaling in a number of neural pathways involved in reward, habit formation, and executive 
function (Volkow et al, 2013a). Additionally, many projections from the lateral hypothalamus, a 
region known for intense involvement in modulating feeding behavior, extend to regions 
otherwise implicated in drug and reward behavior, including the nucleus accumbens, ventral 
tegmental area, and prefrontal cortex (Fadel and Deutch, 2002; Kampe et al, 2009) 
 A number of hypothalamic peptides with known roles in feeding behavior have also been 
implicated in controlling neurobiological responses to drugs of abuse, including ethanol.  To this 
end, a growing literature has indicated anatomical and functional interactions between 
melanocortin signaling and the dopamine system. Melanocortin neuropeptides and receptors 
(particularly MC4R) are abundantly expressed in regions high in dopamine, such as the nucleus 
accumbens and the dorsal striatum (Alvaro et al, 1996; Jacobowitz et al, 1978), and 
melanocortin agonism has also been shown to increase dopamine release in these same areas 
(Florijn et al, 1993). Thus it is not particularly surprising that accumbal melanocortin signaling 
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has been shown to modulate the rewarding effects of cocaine (Hsu et al, 2005). Further, the 
melanocortin system has been tied to opiate tolerance and withdrawal (Alvaro et al, 1997; 
Szekely et al, 1979), and repeated opiate exposure has been shown to modulate MC4R 
expression (Alvaro et al, 1996). 
The Melanocortin System and Ethanol 
 Converging evidence indicates that the melanocortin system plays a particularly 
important role in modulating some neurobiological responses to ethanol. In fact, a recent report 
indicated an interesting overlap in melanocortin control of feeding and ethanol consummatory 
behaviors, as ethanol availability modified the orexigenic ability of site-directed MC4R 
antagonism (Lerma-Cabrera et al, 2012). These data, in addition to the data discussed below, 
further support overlapping neural pathways controlling food and ethanol intake.  
 Early evidence suggesting that the melanocortin system may modulate ethanol-related 
behaviors comes from studies involving alcohol-preferring (AA) rats, animals that are selectively 
bred for their innate tendency to voluntarily consume alcohol, and their non-preferring (ANA) 
counterparts. Ventricular administration of the potent melanocortin agonist MTII immediately 
and significantly blunted ethanol intake (and ethanol preference) in AA rats, an effect that lasted 
for several days following drug administration (Ploj et al, 2002). Shortly thereafter, it was 
discovered that AA and ANA rats display significantly different expression patterns of key 
components of the melanocortin system (Lindblom et al, 2002b). For example, AA rats display 
elevated POMC expression in the ARC relative to ANA rats, along with a reduced level of AgRP 
mRNA, suggesting that the divergence in ethanol drinking displayed by AA and ANA rats may 
be related to innate differences in α-MSH/AgRP ratios. Further, this report noted that AA and 
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ANA rats displayed differential expression of MC3R and MC4R in a number of regions, 
including various nuclei of the hypothalamus and nucleus accumbens (Lindblom et al, 2002b).  
In accordance with these data, it has also been shown that ethanol experience directly 
influences key components of the melanocortin system. For example, ethanol exposure elicits 
substantial effects on hypothalamic POMC mRNA, although the directions of such effects 
appear somewhat dependent on the length and modality of ethanol exposure (Angelogianni and 
Gianoulakis, 1993; Zhou et al, 2000). Long-term ethanol exposure has been repeatedly linked 
with a significant reduction in α-MSH, an effect detected following both exposure to an ethanol-
containing diet or extended passive exposure to ethanol vapor (Navarro et al, 2008; Rainero et 
al, 1990; Wilkinson et al, 1986). In concurrence with these data, Sprague-Dawley rats 
chronically exposed to an ethanol diet displayed not only a significant reduction in POMC, but 
also a significant reduction in the prohormone convertase (responsible for the post-translational 
processing that cleaves POMC into a number of diverse peptides) PC1/3 in the ARC relative to 
control-fed rats (Navarro et al, 2013). Interestingly, Sprague-Dawley rats undergoing a period of 
abstinence following chronic ethanol exposure have also been shown to exhibit region-specific 
increases in α-MSH immunoreactivity (Kokare et al, 2008).  
Both central and peripheral infusion of a non-selective melanocortin agonist have been 
shown to reduce ethanol consumption in C57BL/6J mice, as well as ethanol consumption and 
preference in alcohol-preferring AA rats (Navarro et al, 2005; Ploj et al, 2002; Shutter et al, 
1997). Additionally, while central melanocortin agonism blunts 8 hr ethanol drinking, this effect 
is blocked by a non-selective melanocortin agonist (Navarro et al, 2003). Acute administration of 
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ethanol has also been shown to increase hypothalamic immunoreactivity of the endogenous 
melanocortin antagonist AgRP (Cubero et al, 2010; Navarro et al, 2009). 
The development of mutant mice lacking key components of the melanocortin system 
have allowed further investigation into the role of this system in modulating ethanol drinking 
behavior. In a two-bottle choice procedure, which allows measurement of not only ethanol 
drinking but also ethanol preference, mice lacking the MC4R showed normal ethanol 
consumption relative to wild-type littermates. However, central infusion of MTII reduced 
ethanol intake in wild-type, but not MC4R knockout animals, suggesting that the MC4R is 
necessary for central action of this agonist on ethanol drinking (Navarro et al, 2011). In contrast, 
MTII was effective at reducing ethanol intake in mice lacking the MC3R. Together, these data 
suggest that the MC4R, but not the MC3R, modulates these melanocortin agonist-induced 
reductions in ethanol consumption (Navarro et al, 2005). Further, mice lacking normal 
production of AgRP displayed reduced self-administration of an 8% ethanol solution (but normal 
sucrose, saccharin, and water self-administration) relative to their wild-type counterparts. 
Additionally, these AgRP knockout mice also displayed blunted binge-like ethanol drinking 
using the “drinking in the dark” (DID) protocol; together, these data suggest that endogenous 
AgRP signaling is important in modulating the reinforcing properties of ethanol (Navarro et al, 
2009). Finally, recent observations have suggested that the MC3R may contribute to the 
modulation of binge-like ethanol drinking behavior by serving as an inhibitory autoreceptor 
controlling endogenous MC4R signaling (unpublished observations, J.J. Olney). In sum, these 
data suggest that the melanocortin system plays a key role in modulating a number of 
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neurobiological responses to ethanol. To date, the role of this system in modulating binge-like 
ethanol drinking has only briefly been examined, and thus warrants further investigation. 
The Lateral Hypothalamus 
 A noted above, the MC4R is most highly expressed within hypothalamic nuclei, 
including the LH, a region that receives dense innervation from POMC and AgRP neuron 
originating from the ARC (Elias et al, 1999). This large and functionally heterogenous structure 
first gained considerable interest in the early 1950s, when it was shown that the LH plays a 
crucial role in modulating feeding behavior: an electrolytic lesion of this structure caused rats to 
completely inhibit feeding and die of starvation (Anand and Brobeck, 1951). Parallel studies 
highlighted the ability of this region to robustly support electrical self-simulation and suggested 
that this region is also critically involved in reward and appetitive motivational processes 
(Berthoud and Munzberg, 2011; Hoebel et al, 1962). Further, Marchant and colleagues, 
following functional inactivation of this region, reported that the LH is critical for context-
induced reinstatement of both alcoholic beer and sucrose seeking behavior, indicating that this 
region plays a critical role in learning about and responding to reward-associated stimuli 
(Marchant et al, 2009). Given the known roles of this region in modulating feeding behavior and 
reward behavior, the LH has become an interesting focus of investigation regarding 
neurobiological responses to ethanol, a caloric substance that also has rewarding properties that 
extend well beyond fulfilling a nutritional need. Given these data, the LH has also become a 
particularly attractive target for examining where overlapping neural circuits controlling food 
and drug reward may intersect. 
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 Progress in this realm has been somewhat slow, however, due to the innate characteristics 
of the LH. Thus despite an abundance of research into this region over the last half century, and 
the incredible amount that has been learned about some of the behaviors controlled by this 
region, a complete understanding of the functionality and connectivity both within and extending 
from this region has not yet been accomplished. This is due, in part, to the complex cellular and 
chemical heterogeneity that is characteristic of this region. However, recent work has indicated 
that two main neuronal populations, whose distribution patterns serve to anatomically define the 
LH, expressing either MCH or orexin/hypocretin, may be potential targets for projections from 
the ARC (Elmquist et al, 1999; Swanson et al, 2005). Indeed, both MCH and orexin have been 
associated with reward processing, drug abuse, and alcohol seeking behaviors (DiLeone et al, 
2003; Harris et al, 2005; Lawrence et al, 2006).  Previous work has shown that POMC and 
AgRP neurons originating from the ARC project to the LH, a region rich in MC4R; this region 
also has a dense population of neurons expressing MCH, a functional antagonist of α-MSH 
neurons at the MC4R. Further, research suggests that orexin-expressing neurons within the LH 
may be the target of MC4R LH neurons via a local circuit (Cui et al, 2012). To date, the role of 
melanocortin receptor signaling, particularly within the lateral hypothalamus, has not been 
investigated insofar as modulating binge-like ethanol drinking.  
Goals of the Current Dissertation 
 The overarching goal of the current dissertation is to investigate the role of the central 
melanocortin system, a complex neuropeptide system with known involvement in a number of 
neurobiological responses to ethanol, in binge-like ethanol drinking. To this end, a series of 
experiments will use immunohistochemical and site-directed pharmacological methods, in 
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combination with the “drinking in the dark” protocol, to explore the guiding hypothesis that not 
only is the melanocortin system affected by voluntary ethanol exposure, but also that 
manipulation of this system is sufficient to significantly modulate excessive ethanol intake in 
C57BL/6J mice. The findings of this dissertation will thus provide further insight into the 
neurobiological mechanisms that may underlie high levels of ethanol intake by non-dependent 
mice, and will help expand the current understanding of the role of the melanocortin system in 
ethanol intake. Further, data obtained from this dissertation may provide insight into potential 
therapeutic targets aimed at preventing the development of alcohol dependence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER  2 
 
THE EFFECTS OF REPEATED BINGE-LIKE ETHANOL CONSUMPTION 
ON THE MELANOCORTIN SYSTEM 
 
 
Introduction 
Despite an abundance of research into the neurobiological mechanisms underlying binge 
alcohol (ethanol) drinking, the molecular underpinnings of this behavior remain unclear. A 
“binge,” as defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), is a 
pattern of excessive ethanol consumption that brings an individual’s blood ethanol concentration 
(BEC) to 0.08 grams percent or above within a short time period (NIAAA, 2004). This pattern of 
drinking has been associated with a decrease in general health, a variety of specific long-term 
health risks (Fan et al, 2008b; Okoro et al, 2004; Sundell et al, 2008), and an increased tendency 
to engage in risky behaviors, (Miller et al, 2007; Naimi et al, 2003). Several recent studies have 
also indicated that binge drinking early in life is associated with a greater risk of developing 
alcohol dependence later in life (Courtney and Polich, 2009; Hingson et al, 2006a; Hingson et al, 
2006c; Miller et al, 2007). 
These abundant negative consequences of binge drinking warrant investigation into the 
neurobiological mechanisms underlying this destructive behavior. To this end, the “drinking in 
the dark” (DID) procedure has been established as a preclinical model of human binge drinking 
and has been used to elucidate a number of neuromodulatory systems playing a role in this 
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behavior (Rhodes et al, 2005; Sprow et al, 2012). By capitalizing on the natural drinking patterns 
of mice, this procedure reliably generates high levels of voluntary ethanol consumption, often 
exceeding 80 mg/dl, in a 2-4 hr time span (Lowery et al, 2010; Sparta et al, 2008).  
Recent data have indicated that the melanocortin system, which consists of 5 G-protein 
coupled receptors (MC1R-5R) and includes peptides cleaved from the polypeptide precursor pro-
opiomelanocortin (POMC), modulates neurobiological responses to ethanol. Chronic ethanol 
increases hypothalamic POMC mRNA levels relative to control rats (Angelogianni et al, 1993), 
and high ethanol-drinking AA rats have altered levels of MC3R and MC4R in several brain areas 
relative to their low ethanol drinking counterparts (Lindblom et al, 2002b). Additionally, central 
and peripheral infusion of the non-selective melanocortin receptor agonist melanotan II (MTII) 
reduces ethanol consumption in C57BL/6J mice and ethanol consumption and preference in 
alcohol-preferring AA rats (Navarro et al, 2005; Ploj et al, 2002). Agouti-related protein 
(AgRP), an endogenous melanocortin receptor antagonist, also modulates ethanol intake (Shutter 
et al, 1997). Mice lacking AgRP show are protected against binge-like ethanol drinking, and 
acute administration of ethanol significantly increases hypothalamic AgRP immunoreactivity 
(AgRP IR) in C57Bl/6J mice (Cubero et al, 2010; Navarro et al, 2009). This neuropeptide, 
produced in the hypothalamus, is secreted into the same synaptic complexes as α-melanocyte 
stimulating hormone (α-MSH), a tridecapeptide derived from POMC that is prevalent in brain 
regions involved in neurobiological responses to ethanol, including the hypothalamus and 
extended amygdala (Jacobowitz et al, 1978; O'Donohue et al, 1980; O'Donohue et al, 1979). 
Reduced α-MSH IR has been detected in these regions following chronic exposure to an ethanol 
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diet (Navarro et al, 2008), and region-specific increases in α-MSH IR have been detected in 
abstinent Sprague Dawley rats following chronic ethanol exposure (Kokare et al, 2008).  
  The present study was designed to assess the role of endogenous melanocortin peptides in 
binge-like ethanol consumption. To this end, separate groups of mice experienced 1, 3, or 6 
cycles of binge-like ethanol drinking using the DID protocol. Following the final drinking 
session, all animals were sacrificed and the expression of α-MSH and AgRP in key brain regions 
was examined using immunohistochemical techniques. Although all ethanol-drinking mice 
displayed similar ethanol consumption and BECs following their final test session, we observed 
significant alterations in both α-MSH IR and AgRP IR in several hypothalamic brain areas 
previously implicated in neurobiological responses to ethanol. Together, these observations 
support a role for the melanocortin system, particularly within the lateral hypothalamus, in 
modulating binge-like ethanol consumption.  
Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratories) were 6-8 weeks of age and weighed approximately 
23.5 g at the beginning of experimental manipulations. Mice were individually housed in 
polypropylene cages with corncob bedding and allowed to habituate to the environment for one 
week prior to study initiation. Animals had ad libitum access to food and water except where 
noted below. The animal colonies were maintained at approximately 22° Celsius with a 12h:12h 
light:dark cycle (lights off at 0700 h or 1300 h). All procedures and protocols used in the present 
study were in accordance with the National Institute of Heath guidelines and were approved by 
the University of North Carolina Institutional Animal Care and Use Committee.  
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Drugs 
Ethanol (20%, v/v) solutions were prepared using 95% ethyl alcohol (Decon Laboratories, King 
of Prussia, PA) and tap water. Sucrose (3%, w/v) solutions were prepared using D-Sucrose 
(Fisher Scientific, Fair Lawn, NJ) and tap water. Control animals received bottles containing 
fresh tap water during experimental periods. 
Drinking in the Dark (DID) Procedures  
Animals underwent a 4 day DID procedure previously used in our laboratory (Lowery et al, 
2010; Sparrow et al, 2012; Sparta et al, 2008) to model binge-like drinking. On Days 1-3, water 
bottles were removed from the home cage 3 h into the dark cycle. Bottles containing either 20% 
(v/v) ethanol or 3% (w/v) sucrose were weighed to the nearest 0.1 gram and immediately placed 
on cages. After 2 h the bottles were removed from the cages and again weighed to the nearest 0.1 
g. Following this 2 h period the original water bottles were replaced on the cages and the mice 
left undisturbed until the next day. On Day 4, an identical procedure was followed with the 
exception that ethanol (or sucrose) access was extended to 4 h. Control ethanol and sucrose 
bottles were placed on an empty cage every day of the study to control for fluid spillage and 
evaporation. The average fluid lost from these control bottles was determined at the end of each 
binge-like drinking session and the daily ethanol and sucrose consumption values were adjusted 
accordingly.   
Blood Ethanol Concentrations (BECs) 
To assess blood ethanol concentrations in ethanol-binging mice, a small nick was made at the tip 
of the tail and approximately 10-15μl of blood was collected in heparinized capillary tubes 
(Fisher Scientific, Pittsburgh, PA). Blood samples were centrifuged to separate the plasma from 
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the blood; 5μl of plasma was analyzed using the Analox Blood Analyzer (Analox Instruments 
USA, Lunenburg, MA). Data is reported as mg/dl; the BEC required to meet the NIAAA 
definition of a “binge” is 80 mg/dl, and many animals exceeded the more restrictive criteria of 
100 mg/dl that has previously been suggested  (Crabbe et al, 2011). 
Perfusions, Brain Preparation, and Immunohistochemistry (IHC) 
Perfusion and IR procedures were based on those routinely used in our laboratory (Hayes et al, 
2005). Immediately following the final cycle of binge-like drinking, mice were anesthetized with 
a cocktail of ketamine (117 mg/kg) and xylazine (7.92 mg/kg) and transcardially perfused with 
ice-cold solutions of 0.1 mM phosphate buffered saline (PBS) followed by 4% paraformaldehyde 
in PBS. Brains were collected and post-fixed in paraformaldehyde for 48 h at 4°C and transferred 
to PBS until slicing. Brains were cut into four sets of 40 μm slices using a vibratome and stored 
in either PBS or cryopreserve until IHC processing.  
Sections were transferred into PBS 24 h before processing with antibodies raised against 
α-MSH (Millepore, Temecula, Ca; 1:20000), AgRP (Phoenix Pharmaceuticals, Inc., Burlingame, 
CA; 1:4000), or NeuN (Millipore, Temecula, CA; 1:1000).  After rinsing in fresh PBS 5 times 
(10 minutes each), tissue sections were blocked in the appropriate serum (α-MSH, 10% rabbit; 
AgRP, 10% goat; NeuN, 10% horse) and 0.1% triton-x-100 in PBS for 1 h. Sections were then 
transferred to fresh PBS containing the appropriate antibody and agitated for 72 h at 5°C. As a 
control to determine if staining required the presence of the primary and secondary antibodies, 
some sections were run through the assay without either the primary or the secondary antibody. 
In each assay described below, tissue processed without either of the antibodies failed to show 
staining that was evident in tissue processed with the correct antibodies. After the 72 h 
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incubation, tissue sections were rinsed 3 times and processed with Vectastain Elite kits (Vector 
Laboratories, Burlingame, CA) as per the manufacturer’s instructions for standard 
ABC/HRP/diaminobenzadine-based IHC. The staining was visualized by reacting the sections 
with a 3,3’-diamino-benzidine tetrahydrochloride (DAB; Polysciences, Inc., Warrington, PA) 
solution containing 0.05% DAB, 0.005% cobalt chloride, 0.007% nickel ammonium sulfate, and 
0.006% hydrogen peroxide. Tissue sections were mounted on glass slides, air-dried, and cover 
slipped for viewing. 
Digital images of α-MSH immunoreactivity (α-MSH IR), AgRP IR, and NeuN IR were 
obtained on a Nikon E400 Microscope equipped with a Nikon Digital Sight DS-U1 digital 
camera run with Nikon-provided software (Nikon Instruments Inc., Melville, NY). The density 
of the IR in each region was analyzed by an experimenter blind to the treatment conditions using 
Image J software (Image J, National Institute of Health, Bethesda, MD) by calculating the 
percent of the total area showing staining relative to a subthreshold background. The size of the 
each analyzed region was kept constant between animals and groups.  Anatomically matched 
pictures of the left and right sides of the brain were used to produce an average density for each 
brain region from each slice.  Great care was taken to match sections through the same region 
and at the same level using anatomical landmarks with the aid of a mouse stereotaxic atlas 
(Franklin, 1997). 
Experimental Outline 
To assess the effect of multiple cycles of binge-like ethanol consumption on IR, separate groups 
of C57BL/6J mice experienced 1, 3, or 6 cycles of binge-like ethanol (20%, v/v) or sucrose (3%, 
w/v) drinking (one cycle per week, each cycle separated by 3 off days), as described above.  
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Mice were placed into one of seven groups (n = 10 per group): 1-ethanol (EtOH), 1-sucrose 
(Suc), 3-EtOH, 3-Suc, 6-EtOH, 6-Suc, and continuous water control (WAT). Mice in the WAT 
group were handled exactly the same as mice in the experimental groups and received bottles 
containing fresh tap water during the 2 h and 4 h experimental sessions. The initiation of binge-
like drinking was staggered such that all animals began the final binge-like drinking cycle at 
approximately the same age. Immediately following the final binge-like drinking session, tail 
blood samples were taken from each animal that experienced binge-like ethanol drinking.  Tail 
blood samples were also collected from sucrose-binging and water control animals in order to 
control for potential effects of stress on the IR of melanocortin peptides.  Following the tail 
blood collection, animals were anesthetized and transcardially perfused such that tissue could be 
processed for IHC analysis.  
Data Analysis 
One-way analyses of variance (ANOVAs) were used to assess the differences between groups 
(1-EtOH, 3-EtOH, 6-EtOH) in total ethanol consumed and BEC following the final 4 h binge-
like drinking session.  Identical analyses were used to assess group differences (1-Suc, 3-Suc, 6-
Suc) in 4 h binge-like sucrose consumption during the final session. ANOVAs were also used to 
assess group differences in α-MSH IR, AgRP IR, and NeuN IR as a function of binge-like 
ethanol consumption versus water intake or of binge-like sucrose consumption versus water 
intake. LSD post-hoc tests were used to determine specific differences in IR and behavior 
between the continuous water and all other groups. Significance was accepted at p<0.05; all data 
is presented as mean ± SEM. For BEC measurements as well as IR data, some animals were 
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excluded from analysis (due to lost blood sample or unclear IR staining), which accounts for 
differences in degrees of freedom between similar analysis.  
Results 
No between-groups differences in binge-like ethanol intake or BECs 
Mice in the 1-EtOH, 3-EtOH, and 6-EtOH groups (n = 10/group) consumed similar 
amounts of ethanol during the final binge-like drinking session (5.71 ± 0.50, 5.77 ± 0.35, 6.36 ± 
0.33 g/kg/4 h, respectively; F(2,27)= 0.811, p=0.455), as seen in Figure 2.1A.  Similarly, there 
were no significant differences between groups (n = 9/group; 3 blood samples lost before 
analysis) in terms of BECs achieved during this session (133.06 ± 17.84, 162.59 ± 9.64, and 
188.82 ± 19.44 mg/dl; F(2,24)=2.958, p=0.071; Figure 2.1B). Thus despite experiencing 
different numbers of binge-like ethanol drinking cycles, mice in all ethanol-drinking groups (1-
EtOH, 3-EtOH, 6-EtOH) displayed similar ethanol consumption and BECs on the final binge-
like drinking session. Additionally, mice in the 1-Suc, 3-Suc, and 6-Suc groups (n = 10/group) 
did not significantly differ in terms of total sucrose consumed during the final binge-like 
drinking session (246.52 ± 29.5, 272.90 ± 35.08, and 350 ± 28.16 ml/kg/4h, respectively; 
F(2,27)=3.005, p=0.066; Figure 2.1C). Finally, animals in the ethanol-drinking groups (26.45 ± 
0.36, 27.17 ± 0.32, and 26.98 ± 0.49 g) and sucrose-drinking groups ((26.82 ±0.40, 28.33 ± 1.05, 
and 27.44 ± 0.37 g) displayed similar body weights at the end of the study (F(5,54)=1.332, 
p=0.265).  
Binge-like ethanol consumption leads to a reduction in α-MSH IR 
Based on previous work showing a reduction of α-MSH IR in rats exposed to an ethanol 
diet (Navarro et al, 2008), α-MSH IR was examined in key brain regions following 1, 3, or 6 
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cycles of binge-like drinking of either 20% ethanol or 3% sucrose. Representative 
photomicrographs of α-MSH IR from ethanol-binging mice (top row) and water-drinking control 
mice (bottom row) can be seen in Figure 2.2. Images are from the lateral hypothalamus (LH; A 
and E), dorsomedial hypothalamus (DMH; B and F), arcuate nucleus of the hypothalamus (ARC; 
C and G), and the paraventricular nucleus of the hypothalamus (PVN; D and H). 
LH Data: Figures 2.3A-B show α-MSH IR in the LH following 1, 3, or 6 binge-like drinking 
sessions of 20% ethanol or 3% sucrose. Binge-like ethanol drinking was associated with a 
significant downregulation of α-MSH IR (F(3,27)=5.481, p=0.004);  post-hoc analysis confirmed 
that mice in all binge-like ethanol drinking groups (1-EtOH, 3-EtOH, and 6-EtOH) showed 
blunted α-MSH IR relative to water drinking control animals. Importantly, this decrease 
appeared after just one binge-like drinking cycle, suggesting that α-MSH IR within this region is 
particularly sensitive to the effects of binge-like ethanol drinking. A non-significant one-way 
ANOVA (F(3,28)=0.785, p=0.512) performed on sucrose drinking animals (1-Suc, 3-Suc, 6-Suc) 
confirmed that this decrease in α-MSH IR was specifically associated with binge-like ethanol 
consumption.  
DMH Data: α-MSH IR following 1, 3, or 6 binge-like drinking sessions of 20% ethanol or 3% 
sucrose is shown in Figures 2.3C-D. Relative to control mice, mice that experienced multiple 
binge-like ethanol drinking sessions showed a significant reduction in α-MSH IR 
(F(3,27)=3.561, p=0.027). Post-hoc analysis confirmed that mice in both the 3-EtOH and 6-
EtOH groups showed a significant reduction in α-MSH IR relative to WAT mice. A similar 
analysis performed in sucrose binging groups showed no differences between sucrose drinking 
groups and the WAT group (F(3,22)=0.165, p=0.919). Thus the reduction in α-MSH IR in the 
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DMH was specific to binge-like ethanol consumption and only appeared following 3 or 6 binge-
like ethanol drinking cycles.  
ARC Data: We assessed α-MSH IR in the ARC following 1, 3, or 6 binge-like drinking sessions 
of 20% ethanol or 3% sucrose (Figures 2.3E-F). A one-way ANOVA revealed that repeated 
ethanol exposure also blunted α-MSH IR in this region (F(3,24)=3.258, p=0.039) and post-hoc 
analysis confirmed that α-MSH IR in the 6-EtOH group was blunted relative to both WAT and 
1-EtOH groups. A non-significant ANOVA on data from the sucrose drinking groups confirmed 
this decrease in α-MSH IR was specific to multiple cycles of binge-like ethanol consumption 
(F(3,25)=0.736, p=0.540).  
PVN Data: Figures 2.3G-H show α-MSH IR in the PVN following repeated binge-like drinking 
cycles of 20% ethanol or 3% sucrose. A one-way ANOVA performed on the ethanol drinking 
groups was significant (F(3,30)=3.109, p=0.041), and post-hoc analysis revealed that only the 6-
EtOH group had significantly reduced staining relative to the WAT control group.  A similar 
analysis confirmed that there were no significant changes in α-MSH IR in sucrose drinking 
groups (F(3,28)=1.906, p=0.152). Thus, the decrease in α-MSH IR was specific to ethanol binge-
like consumption and required multiple binge-like drinking cycles to emerge. 
No changes in α-MSH IR were detected in the nucleus accumbens core (NacC), nucleus 
accumbens shell (NacSH), central amygdala (CeA), medial amygdala (MeA), and dorsomedial 
and ventral regions of the bed nucleus of the stria terminalis (dmBNST and vBNST, 
respectively). Non-significant one-way ANOVAs also confirmed a lack of changes in any of 
these regions regards to total sucrose consumption. See Tables 2.1A-B for a summary of α-MSH 
IR data. Taken together, these data show that repeated cycles of binge-like ethanol consumption 
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are associated with a general decrease in α-MSH IR specific to regions of the hypothalamus, 
consistent with previous work from our laboratory (Navarro et al, 2008).  Importantly, although 
in some regions the decrease in α-MSH IR did not became apparent until mice had experienced 
multiple cycles of binge-like ethanol consumption (DMH, ARC, PVN), decreases in α-MSH IR 
in the LH were detected after a single binge-like drinking cycle, suggesting that melanocortin 
signaling in this region is critical in the modulation of neurobiological responses associated with 
binge-like ethanol drinking. 
Repeated cycles of binge-like ethanol consumption lead to an increase in AgRP IR in the PVN  
Given previous data from our laboratory showing that elimination of endogenous AgRP 
protects against binge-like ethanol consumption (Navarro et al, 2009), we examined central 
AgRP IR following 1, 3, or 6 binge-like drinking cycles with either 20% ethanol or 3% sucrose. 
Representative photomicrographs of AgRP IR in the PVN of ethanol binge-like drinking mice 
(A) and water drinking control mice (C) can be seen in Figure 2.4. 
PVN Data: AgRP IR in the PVN following 1, 3, or 6 binge-like drinking sessions of 20% ethanol 
or 3% sucrose is shown in Figure 2.5A-B. Binge-like ethanol drinking was associated with an 
increase in AgRP IR in this region (F(3,26)=19.842, p<0.001); post hoc analysis confirmed that 
the 6-EtOH group showed significantly increased AgRP IR relative to WAT, 1-EtOH, and 3-
EtOH groups.  This increase was specific to ethanol, as a similar analysis performed on the 
sucrose drinking groups was not significant (F(3,27)=2.346, p=0.095).   
One-way ANOVAs of AgRP IR were non-significant in all other regions examined, 
including the LH, ARC, DMH, dmBNST, vBNST, and CeA. Similar analyses performed on 
sucrose drinking groups in these regions also yielded non-significant results; see Tables 2.2A-B 
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for a summary of AgRP-IR data. Together with previous data from our laboratory (Navarro et al, 
2009), these IR data suggest that AgRP signaling within the hypothalamus may modulate binge-
like ethanol drinking. 
Repeated cycles of binge-like ethanol consumption do not change NeuN IR 
As a control to determine if the decreases detected in α-MSH IR were potentially 
secondary to neuronal death stemming from binge-like ethanol drinking, we analyzed the 
neuronal density in regions that showed decreases in α-MSH IR using NeuN, a marker for 
neuron-specific nuclear proteins. Representative photomicrographs of NeuN IR in the LH are 
shown in Figures 2.4(B,D). Importantly, none of the regions that showed decreases in IR 
following 1, 3, or 6 cycles of binge-like ethanol drinking (LH, DMH, ARC, and PVN) showed 
any decreases in neuronal density as measured by NeuN IR (Figure 2.6). Similarly, no 
significant changes in NeuN IR were detected in sucrose drinking groups in any of the regions 
examined. See Tables 2.3A-B for a summary of NeuN IR in these regions. Importantly, these 
results confirm that the reductions detected in α-MSH IR were not likely related to ethanol-
induced neuronal loss.  
Discussion 
The present experiments examined the expression of melanocortin peptides in key brain 
regions following repeated cycles of binge-like ethanol consumption and provide compelling 
evidence for the role of melanocortin peptides in modulating binge-like ethanol consumption in 
C57BL/6J mice. Interestingly, mice that experienced repeated cycles of binge-like ethanol 
drinking did not display an escalation of ethanol intake or a change in ethanol metabolism over 
the 6 week experimental period, as all mice consumed similar amounts of ethanol during, and 
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achieved similar BECs following, the final binge-like testing session. The lack of gross 
behavioral and metabolic differences in these animals is particularly interesting in light of the 
significant changes observed in the expression of the melanocortin peptides α-MSH and AgRP. 
This divergence suggests that the neuroadaptive changes resulting from binge-like ethanol 
consumption may appear long before gross behavioral changes (i.e., changes in drinking 
behavior) manifest, or are important for maintain ongoing binge-like drinking behavior. Given 
the robust levels of ethanol intake observed under this excessive drinking protocol, it is possible 
that the lack of escalation in ethanol intake observed over the repeated cycles of binge-like 
drinking may also be related to a ceiling effect. Importantly, as total intake and BECs were 
similar between all ethanol-consuming groups, it is unlikely that any observed changes in α-
MSH IR or AgRP IR reflect differing levels of ethanol on board at the time of sacrifice.  
Immunohistochemical analysis of the central melanocortin neuropeptide α-MSH and the 
endogenous melanocortin receptor antagonist AgRP following repeated binge-like ethanol 
exposure revealed an overall trend for a blunting of α-MSH expression and an augmentation of 
AgRP expression within regions of the hypothalamus. Given the observed decreases in α-MSH 
IR, NeuN IR was examined to determine whether these decreases were secondary to potential 
neurotoxic effects of repeated binge-like ethanol consumption.  As no changes in NeuN IR were 
detected in any region showing significant reductions in α-MSH IR, these data support the notion 
that the decreases in α-MSH IR may reflect disruptions in normal neuropeptide function rather 
than general neuronal loss.  
Importantly, no changes in either α-MSH IR or AgRP IR were detected in animals that 
experienced one or more cycles of binge-like sucrose consumption, indicating a specificity of 
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these observations to ethanol experience. In general, the observed decreases in α-MSH are in 
agreement with previous work in which Sprague-Dawley rats exposed to a chronic ethanol diet 
showed a decrease in α-MSH IR in several regions, including the LH and the ARC (Navarro et 
al, 2008). Surprisingly, data from the present experiment did not completely align with this 
earlier work, as no changes were detected either the CeA or the BNST, but alterations were 
detected in the DMH and PVN. Several experimental differences separate these studies and may 
partially account for these discrepancies, including the species examined (mouse vs. rat), the 
method of ethanol administration (voluntary binge consumption vs. ethanol diet) and total 
duration of ethanol exposure. Additionally, the particularly low levels of α-MSH detected in the 
CeA of control mice in the present study may have lead to a floor effect in which it was 
impossible to detect significant decreases in α-MSH IR in this region.  
As the decrease in α-MSH IR associated with binge-like ethanol drinking was detected in 
a specific subset of regions, alteration of α-MSH resulting from such ethanol exposure appears to 
be a localized phenomenon and not indicative of a global response to excessive ethanol 
consumption. Further, as no significant changes were detected in sucrose drinking control 
groups, it is unlikely that the observed blunting and augmentation of the melanocortin peptides is 
a general response to salient reinforcers and/or caloric substance, an important consideration 
given the modulatory role of this system in food intake, body weight, and energy homeostasis 
(Cansell et al, 2012; Shimizu et al, 2007). Additionally, our laboratory has previously shown that 
binge-like ethanol drinking using an identical DID protocol is unlikely motivated by caloric need 
(Lyons et al, 2008). Importantly, given that loss of function of the MC4R has been associated 
with body weight dysregulation in both rodent and human populations (Farooqi et al, 2003; 
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Huszar et al, 1997), mice in all ethanol-binging groups maintained similar bodyweights 
throughout the duration of the experiment; thus it is unlikely that perturbations of energy balance 
resulting from ethanol drinking account for the changes in the expression of α-MSH or AgRP IR. 
Together, these data support earlier findings suggesting that the α-MSH pathways implicated in 
feeding behavior and the neurobiological responses to ethanol, while perhaps overlapping, are 
not identical (Navarro et al, 2008).  
The observed decreases in α-MSH within the hypothalamus were not identical between 
groups that experienced differing numbers of ethanol DID cycles, perhaps indicating that the 
melanocortin system becomes increasingly blunted as ethanol exposure lengthens. For example, 
mice that experienced just one four-day cycle of binge-like ethanol consumption displayed a 
significant decrease in α-MSH IR in the LH, and this decrease persisted (but did not decrease 
further) in animals that received multiple cycles. These data contrast with those of other 
hypothalamic regions that seem to require further binge-like drinking cycles to display similarly 
blunted α-MSH IR, including the DMH ( 3 cycles), the ARC (6 cycles), and the PVN (6 cycles). 
This discrepancy is unlikely due to developmental confounds, as the initiation of drinking 
between experimental groups was staggered such that mice were age-matched at the beginning 
of their final, not initial, binge. As such, the age at which mice were first exposed to ethanol did 
differ between groups, an unavoidable factor given the different lengths of ethanol access 
described herein. However, all mice were of adult age when first presented with ethanol or 
sucrose, regardless of the length of exposure they experienced. All ethanol exposure occurred 
when mice were past the critical developmental stages that occur during adolescence, thus 
precluding this as a potential confound when interpreting between-groups differences in IR 
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alterations. Given this information, the robust decrease observed in LH α-MSH IR may reflect 
properties of the LH that make this structure more susceptible to the effects of binge-like ethanol 
exposure than other hypothalamic subregions. Initially indicated as an important mediator of 
reward-related and motivated behavior over a half a century ago, the lateral hypothalamus has 
been repeatedly implicated in promoting appetitive motivation as well as drug-seeking behavior 
(Marchant et al, 2012). Indeed, hypothalamic neuropeptide systems within this region have been 
indicated as playing a role in reinstatement and drug-seeking behaviors, as cue-induced 
reinstatement of alcohol seeking increased c-Fos expression in LH neurons (Dayas et al, 2008). 
Further, functional bilateral inactivation of this region has also been shown to block context-
induced reinstatement of alcoholic beer seeking (Marchant et al, 2009). Given the widespread 
distribution of the MC4R throughout the brain, including the LH (Kishi et al, 2003), as well as 
the great deal of interconnectivity between the LH and other structures involved in mediating 
both drug reward and neurobiological responses to ethanol (Berthoud et al, 2011; Fadel et al, 
2002) the role of the melanocortin system within this region in ethanol drinking behavior clearly 
warrants further investigation.   
Of course, due caution must be used when interpreting any changes in protein expression 
measured with immunohistochemical techniques (Navarro et al, 2008). Although decreased α-
MSH IR within the hypothalamus may reflect augmented α-MSH signaling (stemming from 
increased synaptic release of α-MSH), we hypothesize that repeated cycles of binge-like ethanol 
consumption instead leads to a disruption in normal α-MSH signaling (stemming from blunted 
synthesis). This hypothesis is supported by previous work showing a suppression of POMC 
mRNA following chronic ethanol exposure (Rasmussen et al, 2002). Further, the observations 
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that melanocortin agonists blunt ethanol intake (Navarro et al, 2005; Navarro et al, 2011), that 
administration of exogenous AgRP increases ethanol intake (Navarro et al, 2005), and that 
genetic deletion of AgRP attenuates binge-like ethanol intake (Navarro et al, 2009) all indicate 
that the stimulation of melanocortin receptors is protective against ethanol intake. The present 
observations, in accordance with our previous work, (Carvajal et al, 2007; Cubero et al, 2010; 
Navarro et al, 2009), suggest the possibility that blunted α-MSH signaling (and a corresponding 
increase in AgRP signaling) may emerge over the course of repeated binge like drinking cycles. 
These changes in signaling patterns may thus weaken the protective effects exerted by the 
melanocortin system, potentially leading to continued binge-like drinking. As noted above, α-
MSH IR in the LH was reduced after just one binge-like drinking episode, thus leading to the 
speculation that this region represents a critical structure that may underlie the motivation to 
exhibit this excessive drinking behavior. 
In regards to the endogenous melanocortin antagonist, only the PVN showed a significant 
increase in AgRP IR; this difference was only apparent in mice that experienced six cycles of 
binge-like ethanol consumption. No changes were detected in any other region in which AgRP 
was detected (including many of the same regions in which decreased α-MSH IR was noted), 
and no changes were observed in sucrose drinking animals. These data resonate with previous 
work from our laboratory showing a dose-dependent increase in AgRP IR in the ARC of mice 
treated with an intraperitoneal injection of ethanol (Cubero et al, 2010). Here again, localization 
of the increase in IR and the specificity of the augmentation to binge-like ethanol drinking adds 
to previous literature indicating an integral role of melanocortin receptor signaling in regulating 
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ethanol consumption, extending these findings to binge-like ethanol consumption (Navarro et al, 
2005; Navarro et al, 2003; Ploj et al, 2002). 
 In sum, the present data extend the current literature supporting a role for the 
melanocortin system in the modulation of binge-like ethanol drinking by showing region-specific 
changes in the expression of an endogenous melanocortin agonist and an endogenous 
melanocortin antagonist following a history of binge-like ethanol drinking. These effects appear 
not only specific to ethanol, as binge-like sucrose consumption did not alter the expression of 
either α-MSH or AgRP, but also dependent on the number of binge-like drinking cycles 
experienced. In light of other data showing long-term alterations in the melanocortin system that 
appear dependent on the specific nature of the ethanol history, it may be that alterations within 
this prolific system play a key role in the ultimate transition from ethanol drinking to ethanol 
dependence. As striking changes in α-MSH IR were detected in the lateral hypothalamus 
following just one cycle of binge-like ethanol drinking, subsequent chapters will utilize site-
directed pharmacological techniques to further explore the role that melanocortin signaling 
within this region plays in modulating binge-like ethanol consumption.  
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
Figure 2.1:  Ethanol consumption, sucrose consumption, and BECs achieved in Experiment 1. 
Total fluid consumed on the final day of binge-like 20% ethanol (A) or 3% sucrose (C) drinking 
did not differ between mice that experienced 1, 3, or 6 cycles binge-like drinking. BECs from the 
final session of binge-like ethanol drinking (B) did not differ between mice that experienced 1, 3, 
or 6 cycles of binge-like ethanol drinking. All data are shown as mean ± SEM, and significance 
was accepted at p<0.05. Dashed line (B) represents 80mg/dl, defined by NIAAA as the BEC 
required for a ‘binge.’ 
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Figure 2.2: Representative photomicrographs depicting α-MSH IR (% total area) in nuclei of the 
hypothalamus: α-MSH in the lateral hypothalamus (A, E), dorsomedial hypothalamus (B, F), 
arcuate nucleus (C, G) and paraventricular nucleus (D, H). The top row are from mice that 
experienced 6 cycles of binge-like ethanol consumption, and the bottom row are from mice that 
consumed only water for the duration of the experiment. Images were captured at a 
magnification of 40x, and the scale bar = 50 μm. 
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Figure 2.3: The effects of binge-like ethanol and sucrose consumption on α-MSH IR. Binge-like 
consumption of ethanol of 20% ethanol, but not 3% sucrose, significantly reduced α-MSH IR in 
the LH (A), DMH (C), ARC (E) and PVN (G).  The left column (A,C,E, G) represents α-MSH 
IR from mice that experienced 1, 3, or 6 cycles of binge-like 20% ethanol consumption, and the 
right column (B, D, F, H) represents mice that experienced 1, 3, or 6 cycles of binge-like 3%  
sucrose consumption. All data are shown as mean ± SEM, and significance was accepted at 
p<0.05. *denotes significance of p<0.05 vs. WAT, ** denotes p<0.01 vs. WAT. 
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Figure 2.4: Representative photomicrographs depicting AgRP IR in the paraventricular nucleus 
(PVN) and NeuN IR in the lateral hypothalamus (LH). The top row depicts mice that 
experienced 6 cycles of binge-like ethanol consumption, and the bottom row depicts mice that 
consumed only water for the duration of the experiment. Images were captured at a 
magnification of 20x, and the scale bar = 100 μm. 
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Figure 2.5: The effects of binge-like ethanol and sucrose consumption on AgRP IR. Binge-like 
consumption of 20% ethanol (A), but not 3% sucrose (B), significantly increased AgRP IR in the 
PVN. All data are shown as mean ± SEM, and significance was accepted at p<0.05. ** denotes 
p<0.01 vs. WAT. 
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Figure 2.6: The effects of binge-like ethanol and sucrose consumption on NeuN IR. Binge-like 
consumption of 20% ethanol did not significantly affect NeuN IR in the LH (A), DMH (B), ARC 
(C), or PVN (D). All data are shown as mean ± SEM, and significance was accepted at p<0.05.  
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LH DMH ARC PVN
Water 7.99 ± 0.47 11.97 ±  0.52 7.15 ± 0.52 8.74 ± 0.50
1-EtOH 8.11 ±  0.38 11.77 ±  0.69 6.78 ±  0.44 8.87 ± 0.45
3-EtOH 8.34 ±  0.54 12.72 ± 0.55 8.06 ±  0.22 8.73 ± 0.63
6-EtOH 7.52 ±  0.41 12.37 ± 0.36 7.16 ± 0.44 8.36 ± 0.31
F-statistic 0.552 0.566 1.072 0.181
p  value 0.651 0.642 0.378 0.908
LH DMH ARC PVN
Water 7.99 ± 0.47 11.97 ± 0.52 7.15 ± 0.52 8.74 ± 0.50
1-Suc 7.99 ± 0.45 11.68 ± 0.58 7.29 ± 0.63 8.24 ± 0.40
3-Suc 8.57 ± 0.54 13.01 ± 0.37 7.03 ± 0.47 8.68 ± 0.45
6-Suc 8.29 ± 0.58 11.6 8 ± .84 7.65 ± 0.59 8.39 ± 0.71
F-statistic 0.272 0.845 0.192 0.24
p  value 0.845 0.481 0.901 0.867
LH, lateral hypothalamus; DMH, dorsomedial hypothalamus; ARC, arcuate nucleus 
of the hypothalamus; PVN, paraventricular nucleus of the hypothalamus
Table 2.3A  Average NeuN IR (% area ± SEM) immediately following 
binge-like ethanol consumption 
LH, lateral hypothalamus; DMH, dorsomedial hypothalamus; ARC, arcuate nucleus 
of the hypothalamus; PVN, paraventricular nucleus of the hypothalamus
Table 2.3B  Average NeuN IR (% area ± SEM) immediately following 
binge-like sucrose consumption 
 
 
 
 
 
 
 
CHAPTER  3 
THE EFFECTS OF SITE-DIRECTED MELANOCORTIN COMPOUNDS 
ON BINGE-LIKE ETHANOL CONSUMPTION 
 
 
Introduction 
The melanocortin system, most well known for its role in the modulation of energy 
homeostasis and feeding behavior (Fan et al, 1997; Thiele et al, 1998), has recently been 
implicated in modulating neurobiological responses to alcohol (Navarro et al, 2005; Navarro et 
al, 2009; Ploj et al, 2002).  Roughly 83% of the population has used alcohol within their lifetime 
(NIAAA 2004), and alcohol use disorders (i.e., alcohol abuse and dependence) are among the 
most prevalent mental disorders not only within the United States but also worldwide (Goetzel et 
al, 2003; WHO, 2003). Binge alcohol drinking is a particularly troubling pattern of drinking 
exhibited by persons of all ages (Nelson et al, 2009), given not only the vast number of 
associated short- and long-term health risks (Miller et al, 2007; Sundell et al, 2008) but also the 
increased proclivity of individuals who binge drink early in life to develop alcohol dependence 
later in life (Hingson et al, 2006a). To date, the role of the melanocortin system in this 
destructive pattern of ethanol consumption has not been thoroughly examined. 
The melanocortin system consists of five G-protein coupled receptors (MC1R-MC5R), 
with MC3R and MC4R the most predominant receptor subtypes distributed throughout the 
rodent brain (Mountjoy et al, 1994). These receptors are acted upon by not only bioavailable 
neuropeptides cleaved from the polypeptide precursor pro-opiomelanocortin (POMC), including 
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the melanocortin agonist α-melanocycte stimulating hormone (α-MSH) (Jacobowitz et al, 1978; 
O'Donohue et al, 1979), but also the endogenous melanocortin receptor antagonist agouti-related 
protein (AgRP). AgRP is co-expressed with neuropeptide Y (NPY) in GABA-releasing neurons 
that largely overlap in their distribution with POMC-expressing neurons (Hahn et al, 1998).  
While both α-MSH and AgRP are found throughout the rodent brain, both peptides are most 
prevalent within the subregions of the hypothalamus. 
As discussed in Chapter 2 of this dissertation, recent work from our laboratory has shown 
that repeated exposure to excessive levels of voluntarily consumed ethanol using a protocol 
designed to mimic binge-like drinking behavior is sufficient to alter the expression of both α-
MSH and AgRP within various hypothalamic nuclei. In general, the directions of these changes 
were in agreement with previous literature examining POMC mRNA (Angelogianni et al, 1993) 
and AgRP immunoreactivity (Cubero et al, 2010) following ethanol challenges. In Chapter 2, we 
found that the most striking changes in α-MSH immunoreactivity in the lateral hypothalamus 
(LH), a region known for modulating not only feeding behavior and homeostatic processes but 
also reward processing via connections to the reward pathways of the brain (DiLeone et al, 
2003). 
The LH first gained substantial interest in the early 1950s, when it was shown that 
electrolytic lesions of this region were sufficient to completely inhibit feeding behavior to such 
an extent that the lesioned rat would die of starvation (Anand et al, 1951). These data quickly 
earned the LH the title of the “feeding” center of the brain, but parallel studies also discovered 
another hallmark characteristic of this region: the ability to robustly support electrical self-
stimulation (Berthoud et al, 2011; Hoebel et al, 1962). Because of the complex cellular and 
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chemical heterogenetity of the LH, as well as the intricate network of fibers that pass through 
this region, a systematic analysis of the functionality and connectivity both within and extending 
from this region has not been accomplished. However, the distribution patterns of two neuronal 
populations that express either melanin-concentrating hormone (MCH; a functional antagonist of 
α-MSH (Nahon, 2006)) or orexin (hypocretin), both suggested targets for projections from the 
arcuate nucleus of the hypothalamus (Elmquist et al, 1999), have improved progress in this realm 
(Swanson et al, 2005). Indeed, since the discovery of the orexin system in the late 1990s (de 
Lecea et al, 1998; Sakurai et al, 1998), an abundance of work has uncovered a highly complex 
neuropeptide system that projects throughout the neuroaxis and is associated with reward 
processing, drug abuse, and alcohol seeking (Harris et al, 2005; Lawrence et al, 2006). Given 
that POMC and AgRP neurons originating from the arcuate nucleus of the hypothalamus project 
to the LH, that the MC4R is broadly expressed within the LH, and that evidence suggests that 
orexin-expressing neurons within the LH may be potential targets of MC4R LH neurons (Cui et 
al, 2012), the role of melanocortin signaling within this region in the role of binge-like ethanol 
consumption warrants further investigation. 
The goal of the present set of experiments was to examine the role of melanocortin 
signaling within the LH in modulating excessive voluntary ethanol consumption using the 
“drinking in the dark” (DID) model of binge-like drinking. Site-directed pharmacological 
techniques were used to agonize or antagonize melanocortin receptors within the LH during a 4 
hr period of binge-like ethanol drinking. To this end, we show that site-directed melanocortin 
agonism within the LH is sufficient to blunt, while site-directed melanocortin antagonism within 
the LH is sufficient to augment, binge-like ethanol consumption. Control studies indicate that 
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this modulation shows both regional and substrate specificity. Additional studies also show that 
while intra-LH melanocortin agonism does not significantly affect water consumption under the 
binge-like drinking protocol, administration of the melanocortin agonist MTII does decrease 
food consumption. Further, both food availability and drug treatment significantly affect ethanol 
preference during the four hour binge-like drinking session, while only food availability affects 
water intake during the drinking session. Together, these data indicate that melanocortin 
signaling within the LH may play a critical role in influencing binge-like ethanol consumption in 
ethanol-preferring C57BL/6J mice. 
Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratories) were 6-8 weeks of age at the beginning of each 
study. Mice were individually housed in polypropylene cages with corncob bedding and allowed 
to habituate to the environment for one week prior to study initiation. Animals had ad libitum 
access to food and water, except where noted below. The animal colonies were maintained at 
approximately 22° Celsius with a 12h:12h light:dark cycle (lights off at 7 a.m. and 10 a.m.). All 
procedures and protocols were in accordance with the National Institute of Heath guidelines and 
were approved by the University of North Carolina Institutional Animal Care and Use 
Committee.  
Drugs   
Ethanol (20%, v/v) solutions for consumption during DID testing were prepared using tap water 
and 95% ethyl alcohol (Decon Laboratories Inc., King of Prussia, PA). Sucrose (10%, w/v) 
solutions were prepared using tap water and D-Sucrose (Fisher Scientific, Fair Lawn, NJ).  All 
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compounds for site-directed infusions were dissolved in sterile saline; as such, sterile saline was 
used as the vehicle control for all infusions. The nonselective melanocortin receptor agonist 
melanotan II (MTII; 0.5nmol/0.5 μl/side; American Peptide, Sunnyvale, CA), the nonselective 
melanocortin receptor antagonist agouti-related protein (AgRP; 0.1nmol/0.5µ l/side; Phoenix 
Pharmaceuticals, Inc., Belmont, CA), and the selective melanocortin-4 receptor (MC4R) agonist 
cyclo(NH-CH2-CH2-CO-His-d-Phe-Arg-Trp-Glu)-NH2 (MC4R agonist; 1.0nmol/5µl/side; 
Phoenix Pharmaceuticals, Inc.) or vehicle were infused approximately 90 min before the start of 
behavioral testing. This time point was chosen in order to temporally separate the infusion and 
ethanol presentation and limit the effect of stress on ethanol intake.  Further, the effects of all 
compounds have previously shown long-lasting effects on food and/or ethanol intake, ranging 
from several hours to several days (Navarro et al, 2005; Ploj et al, 2002).  As we have previously 
assessed the effects of both MTII and AgRP in either wild-type C57BL/6J mice and/or mice 
lacking the MC3R or MC4R, we chose to use these compounds to allow more direct 
comparisons between studies (Navarro et al, 2005; Navarro et al, 2011). Additionally, MTII  has 
been used by other groups to reduce ethanol drinking in an alcohol-preferring rat strain (Ploj et 
al, 2002), and pretreatment with AgRP has been shown to block the effect of MTII in C57BL/6J 
mice in an 8 hr ethanol drinking protocol (Navarro et al, 2003). Finally, as previous work from 
our laboratory has indicated an important role for the MC4R in particular in modulating ethanol 
consummatory behaviors, a separate group of animals received pretreatment with the MC4R 
agonist, a potent agonist at the human MC4R that has been shown to exhibit 90-fold selectivity 
over the MC3R and a greater than 2000-fold selectivity over MC5R (Bednarek et al, 2001).   
Drinking in the Dark (DID) Procedures  
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For Experiments 1-2, animals underwent a 4-day DID procedure previously used in our 
laboratory (Lowery et al, 2010; Navarro et al, 2009; Sparta et al, 2008) to model binge-like fluid 
consumption. Briefly, on days 1-3, water bottles were removed from cages 3 hr into the dark 
cycle. Bottles containing either 20% (v/v) ethanol or 10% (w/v) sucrose were placed on home 
cages and secured in place. Fluid levels were immediately measured to the nearest 0.1 mL. 
Changes in fluid level were monitored hourly; after the 2 hr measurement, the bottles were 
removed from the cages and the original water bottles were replaced on the cages. Mice were left 
undisturbed until the next day. On day 4, the ethanol (or sucrose) access was extended to 4 hr; all 
other procedures were identical to days 1-3. The amount of ethanol consumed during each hour 
of the 4 hr binge test, as well as the total amount consumed over the entire 4 hr period, was 
calculated and is expressed as grams of ethanol per kilogram of body weight (g/kg). 
BECs  
To assess blood ethanol concentrations (BECs) in ethanol-binging mice, immediately after the 
bottles were removed on day 4 a small nick was made at the tip of the tail and approximately 10-
15μl of blood was collected in heparinized capillary tubes (Fisher Scientific, Pittsburgh, PA). 
Blood samples were centrifuged to separate the plasma from the blood; 5μl of the plasma was 
analyzed using the Analox Blood Analyzer (Analox Instruments USA, Lunenburg, MA). Data is 
reported as mg/dl. 
Surgery and Microinfusion Procedures  
Approximately 2 weeks after arrival, mice were anesthetized with a cocktail of ketamine (117 
mg/kg) and xylazine (7.92 mg/kg) and implanted with bilateral 26-gauge cannulae (Plastic One, 
Roanoake, VA) aimed at the lateral hypothalamus (LH; 1.1 mm posterior to bregma, 1.1 mm 
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lateral to the midline, and 5.1 mm ventral to the skull surface) or the bed nucleus of the stria 
terminalis (BNST; 0.25 mm anterior to bregma; 1.1 mm lateral to the midline; 4.1 mm ventral to 
the skull surface) using procedures commonly used in our laboratory (Lowery et al, 2010; 
Sparrow et al, 2012). Mice were allowed to recover for a minimum of one week before the 
initiation of experimental procedures. All cannulae placement was verified histologically at the 
end of the experimental procedures, and any animals with unilateral or bilateral misses were 
excluded from all data analysis. The site-directed infusions were delivered in a 0.5 μl volume 
over a 1 min period using a 1.0 μl Hamilton microsyringe controlled by a Harvard Apparatus 
PHD 2000 microinfusion pump. After the infusion, the injector was left in place for 1 min in 
order to ensure drug diffusion away from the injector. Mice were habituated to this infusion 
procedure 2-4 times before the initiation of the DID cycle.  
Experimental Protocols 
1. Melanocortin agonism and antagonism within the LH 
To assess the effect of intra-LH MC agonism and antagonism on binge-like ethanol 
consumption, mice were randomly placed into one of three groups (n = 9/group):  MTII 
(Experiment 1A), a selective MC4R agonist (Experiment 1B), or AgRP (Experiment 1C). 
Following day 3 of the DID cycle, mice in each group were randomly split into the drug or 
vehicle group based on total ethanol consumed during the last 2 hr DID session such that the 
average consumption under each drug condition was similar. On day 4, approximately 90 min 
before ethanol presentation, mice received a bilateral infusion of the designated compound or 
vehicle. Ethanol consumption was monitored hourly for 4 hr, and tailblood samples were 
collected immediately following bottle remove for BEC analysis.  After three rest days, during 
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which animals had only ad libitum access to chow and tap water in their normal water bottles, all 
mice underwent a second identical cycle of DID in which they received the opposite drug 
treatment in a Latin-square design. Approximately one week later, animals underwent two cycles 
of a sucrose (10%, w/v) DID using procedures identical to those described above, except that no 
tailbloods were collected. Following the final sucrose test, all animals were sacrificed and 
cannulae placement was verified histologically.  
2. Melanocortin agonism and antagonism within the BNST 
As intra-LH MC agonism or antagonism was sufficient to blunt or augment binge-like 
ethanol consumption, respectively, a separate group of mice was surgically implanted with 
bilateral cannulae targeting the BNST to examine site-specificity of the effects observed 
following the LH manipulations. Mice were randomly placed into one of two groups (n = 
9/group):  MTII (Experiment 2A) or AgRP (Experiment 2B). The design of this experiment was 
nearly identical to that of the Experiment 1 except that only MTII or AgRP were infused and no 
sucrose DID was performed in AgRP-treated animals. At the conclusion of this study cannulae 
placement was verified histologically.  
3. Intra-LH Melanocortin agonism: water drinking, ethanol preference and food intake 
As intra-LH melanocortin agonism was sufficient to blunt binge-like ethanol consumption, 
the following experiment was designed to assess the effect of intra-LH melanocortin agonism on 
water consumption, ethanol preference, and food consumption. A separate group of mice (n = 
48; 12 mice/group) cannulated with bilateral cannulae targeting the LH was used for this 
experiment. Approximately one week prior to the initiation of this experiment, these animals had 
undergone one DID cycle during which they received a bilateral infusion of a MEK inhibitor (or 
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vehicle) followed by bilateral infusion of MTII/saline (see Chapter 3 Methods). In the present 
study, animals underwent a modified 4 day DID protocol in which they received three days of 2 
hr access to two identical bottles, one containing fresh tap water and the other containing 20% 
(v/v) ethanol beginning three hours into the dark cycle; as in the previously described DID cycle, 
this access was extended to 4 hr on the final test day. The position of the bottles was alternated 
daily to prevent side bias. Immediately before the beginning of each drinking session, all food 
was removed from the top of the cage and two food pellets were weighed and placed inside the 
cage.  Consumption of ethanol and water was recorded hourly, and total food consumption was 
recorded at the end of each drinking session. At the end of each drinking session, normal water 
bottles were returned to each cage and free food was returned to the top of the cage. Immediately 
before the final test session, all mice received a bilateral intra-LH infusion of either MTII or 
saline, counterbalanced based on ethanol intake from the previous day. Mice received the drug 
infusion immediately prior to ethanol presentation, as earlier studies showed the strongest effect 
of MTII on ethanol consumption within the first half of the drinking session and other  work 
indicated that stress of intracranial microinfusion immediately prior to ethanol presentation does 
not significantly inhibit drinking during the DID protocol (Chapter 3).  During this final test 
session, half of the animals had food available and half of the animals had access to only the 
water and ethanol bottles. At the end of this session, tailbloods were collected for BEC analysis. 
Cannulae placement was verified histologically. 
Data Analysis 
Only animals with bilateral cannulae targeting either the LH or BNST were included in any data 
analysis described herein (Experiment 1: n = 26; Experiment 2: n = 16; Experiment 3: n = 45). 
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As animals in Experiment 1-2 experienced both drug and vehicle in counter-balanced order, 
ANOVAs were used to determine whether there was an effect of treatment order on ethanol 
consumption. As no drug by treatment order interaction was detected in any experiment, data 
were collapsed across groups and paired t-tests were performed to examine between-treatment 
differences in ethanol consumption and BEC achieved. Hourly measures were analyzed with 
repeated-measures ANOVA, with t-tests used to examine between-groups differences at specific 
timepoints. In Experiment 3, 2 x 2 (food availability x drug treatment) ANOVAs were used to 
examine the effects of food availability and drug treatment on food or liquid consumption, 
ethanol preference, and BEC.  All data re presented as mean ± SEM, and significance was 
accepted at p<0.05 (two-tailed).   
Results 
Experiment 1A: MTII in the LH 
A schematic depicting placement of bilateral cannulae in the LH is shown in Figure 
3.1A. The effect the nonselective melanocortin agonist MTII on binge-like ethanol and sucrose 
consumption is shown in Figure 3.2. Animals that received a bilateral intra-hypothalamic 
infusion of MTII prior to ethanol access on the final test session displayed significantly blunted 
levels of ethanol drinking relative to vehicle-treated animals (t(8)=2.684; p=0.028; Figure 3.2A). 
The BECs of MTII-treated animals showed a corresponding, albeit non-significant (t(8)=1.909, 
p=0.093), trend in the same direction (Figure 3.2C). This effect may be partially explained by 
the pattern of drinking over the 4 hr binge test session (Figure 3.2B). Indeed, while a repeated 
measures ANOVA did not indicate a drug by hour interaction, this analysis revealed a between-
subjects effect of drug (F(1,13)=5.185; p=0.031) over the binge test. While MTII-treated animals 
56 
 
drank significantly less than vehicle-treated animals specifically in the first half of the binge test, 
the level of ethanol drinking returned to a level similar to that of control animals in the second 
half of the session. Interestingly, bilateral infusion of MTII into the LH did not have a significant 
effect on sucrose consumption under an identical protocol (t(7)=1.929; p=0.095), indicating a 
specificity of the effect of MTII to binge-like ethanol intake. 
Experiment 1B: MC4R Agonist in the LH 
Ethanol and sucrose consumption following bilateral infusion of a selective MC4R agonist into 
the LH is shown in Figure 3.3. Although MC4R agonist-treated animals did not show a 
significant blunting of binge-like ethanol consumption relative to vehicle-treated animals 
(t(7)=1.650;p=0.143; Figure 3A), they did show a significant decrease in sucrose consumption 
under an identical binge protocol (t(7)=3.020; p=0.019, Figure 3.3B).  Given the short half-life 
of this compound, we also examined ethanol and sucrose consumption during the first (hours 1-
2) and second (hours 3-4) halves of the binge test. Analysis revealed that bilateral infusion of the 
MC4R agonist blunted both ethanol (t(7)=5.154; p=0.001) and sucrose (t(7)=3.379; p=0.012) 
consumption during the first two hours of the session but did not have a significant effect on 
either sucrose or ethanol intake during the final two hours (p>0.05; Figures 3.3C-F). Finally, 
despite only having a significant effect on ethanol drinking during the first half of the binge test, 
MC4R agonism within the LH was associated with lower BECs achieved over the entire session 
(t(7)=2.713; p=0.030; Figure 3.3G).  
Experiment 1C: AgRP in the LH 
 The effect of the nonselective melanocortin antagonist AgRP on binge-like ethanol and 
sucrose consumption is shown in Figure 3.4. Animals that received a bilateral infusion of intra-
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LH AgRP approximately 90 min prior to ethanol presentation displayed significantly elevated 
levels of ethanol consumption relative to vehicle-treated animals during the 4 hr binge session 
(t(8)=-3.343; p=0.010; Figure 3.4A), although there was not a concomitant between-groups 
difference in regards to the BECs achieved over this time (t(8)=-0.068; p=0.948; Figure 3.4B). 
A repeated measures analysis over the four hour binge test revealed a main effect of hour 
(F(3,48)=4.101; p=0.011) and drug (F(1,16)=7.017; p=0.018), although the interaction did not 
reach significance. Further, there was not a significant effect of AgRP treatment on sucrose 
consumption under an identical DID protocol (t(8)=2.1; p=0.069; Figure 3.4C). 
Experiment 2A: MTII in the BNST 
In order to examine the regional specificity of the effects described above to the LH, a 
separate group of mice was surgically implanted with bilateral cannulae targeting the BNST 
(Figure 3.1B). The effect of bilateral intra-BNST infusion of MTII on binge-like ethanol and 
sucrose consumption is shown in Figure 3.5. Interestingly, animals treated with bilateral 
infusions of MTII into the BNST prior to ethanol access displayed significantly lower levels of 
drinking relative to vehicle-treated animals (t(5)=3.158; p=0.025, Figure 3.5A), although these 
animals did not display a similar change in BEC achieved during this time (t(4)=-1.372, p=0.242; 
Figure 3.5B). This effect did not translate to all drinking behavior, as consumption of a 10% 
sucrose solution under an identical design was not significantly decreased in MTII-treated 
animals (t(6)=2.319, p=0.06; Figure 3.5C). Repeated measures ANOVA of the four hour binge 
test revealed a main effect of drug (F(1,13)=5.815, p=0.031), although neither hour nor the 
interaction of hour by drug researched significance. 
Experiment 2B: AgRP in the BNST 
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 Ethanol consumption and BECs from mice treated with bilateral infusion of AgRP or 
vehicle into the BNST prior to the final binge test are shown in Figure 3.6. Mice treated with 
AgRP did not significantly differ from vehicle-treated animals in regards to either total ethanol 
consumption (t(8)=0.535, p=0.607; Figure 3.6A) or the BEC achieved (t(8)=0.642, p=0.539; 
Figure 3.6B). Further, repeated measure analysis across the four hour binge test indicated no 
main effect of drug treatment, and no drug by hour interaction, although there was a significant 
main effect of hour (F(3,48)=5.314, p=0.003): animals in both groups drank the most ethanol 
during the beginning of the session and tapered their drinking over the course of the binge 
session. As this antagonism of the melanocortin system within the BNST did not have a 
significant effect on voluntary binge-like ethanol consumption, mice did not undergo a sucrose 
control DID.  
Experiment 3: Intra-LH MTII, water intake, food consumption, and ethanol preference 
 The effect of intra-LH MTII on ethanol consumption, water consumption, ethanol 
preference, BECs, and food consumption is shown in Figures 3.7-3.8. Mice infused with intra-
LH MTII immediately prior to the final testing session displayed significantly lower ethanol 
consumption over the 4 hr drinking session relative to saline-treated animals (Figure 3.7A). 
Analysis revealed a main effect of drug (F(1,41)=11.951; p=0.001), but no significant effect of 
food availability, on the ethanol consumed. A significant interaction of food availability and drug 
treatment was not observed here or in any of the other results presented below. Figure 3.7B 
shows that there was a main effect of food availability (F(1,41)=34.060; p=0.000), but no effect 
of MTII, on total water consumption. There was also a main effect of food availability on overall 
ethanol preference (F(1,41)=17.736; p=0.000; Figure 3.7C), an effect likely attributed to the 
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increased water consumption in the animals that had food available throughout the session. 
Further, there was an effect of drug treatment on ethanol preference (F(1,41)=4.482, p=0.04), an 
effect likely attributed to the decreased ethanol intake in the absence of a change in water intake. 
Analysis of BECs achieved over the 4 hr drinking session revealed no significant main effect of 
either drug treatment or food availability (Figure 3.7D). Unsurprisingly, pre-treatment with 
intra-LH MTII also reduced food consumption relative to saline-treated animals (t(19)=8.455; 
p=0.009; Figure 3.7E).  
 As there was no significant effect of either food availability or drug treatment on BECs 
achieved, despite robust differences in food, water, and ethanol consumption, we examined 
ethanol and water consumption during the first and second halves of the final test session 
separately (Figure 3.8).  While there was a significant main effect of intra-LH MTII on ethanol 
consumption during the first half of the binge session (F(1,41)=28.408; p=0.000; Figure 3.8A), 
neither the presence of food nor the drug treatment had a significant effect on ethanol 
consumption during the second half of the binge session (Figure 3.8B). Conversely, while 
neither food availability nor drug treatment affected water consumption during the first half of 
the binge session (Figure 3.8C), there was a significant main effect of food availability on water 
consumption during the second half of the final test session (F(1,41)=46.025; p=0.000; Figure 
3.8D). Finally, although there was no between-groups difference in ethanol preference during the 
first 2 hr of the final test session (Figure 3.8E), there was a main effect of food availability on 
the ethanol preference during the second half of the final test session (F(1,40) = 26.005, p=0.000; 
Figure 3.8F).  
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Discussion 
 The present series of experiments utilized site-directed pharmacological techniques to 
examine the role of the melanocortin system within the lateral hypothalamus (LH) in binge-like 
drinking. The results from these studies extend previous findings showing immunohistochemical 
support for this region in binge-like drinking (Chapter 2) as well as earlier work using central 
manipulation of this neuropeptide system to modulate ethanol intake under a separate ethanol 
drinking protocol (Navarro et al, 2003). While ethanol is indeed a caloric compound, it is likely 
that the melanocortin system may be involved in separate but overlapping pathways involved in 
both feeding behavior and binge-like drinking behavior. Here, we show that intra-LH 
melanocortin agonism is sufficient to blunt, while intra-LH melanocortin antagonism is sufficient 
to augment, binge-like ethanol consumption. Further, we show that administration of a 
nonselective melanocortin agonist into this region affects ethanol preference, but does not affect 
water consumption or ethanol preference. These data supplement previous work that has 
indicated not only a critical role for the melanocortin system in food intake and energy 
homeostasis (Pandit et al, 2011) but also a particular role for the melanocortin-4 receptor 
(MC4R) in both feeding behavior (Giraudo et al, 1998) as well as ethanol drinking (Navarro et 
al, 2005; Navarro et al, 2011)  
In the first series of experiments, bilateral infusion of MTII was sufficient to blunt binge-
like ethanol drinking relative to vehicle-treated animals. Although there was not a significant 
decrease in associated BECs, this disconnect is likely due to the pattern of drinking over the 4 hr 
binge test, as previous work has shown that the effects of MTII administration on ethanol 
drinking are not secondary to alterations in ethanol metabolism (Navarro et al, 2003). The most 
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robust blunting of ethanol drinking behavior was observed within the first hour of the drinking 
session, with levels of ethanol intake returning to vehicle-level by later in the session. We 
administered drug compounds in Experiments 1-2 approximately 90 minutes prior to the 
initiation of the drinking cycle, in order to temporally separate the stressful infusion event from 
the presentation of ethanol consumption and to avoid artificially influencing levels of intake. As 
such, the most robust effects of drug treatment on ethanol consumption appeared within the first 
1-2 hrs of the session, an effect that may be related to either the half-life of the drug or 
melanocortin receptor desensitization. This is supported by data from Experiment 3, in which 
bottles were presented immediately following the drug infusion and during which the MTII-
induced blunting of ethanol intake was observed over a longer duration. In the present studies, 
tailblood samples were collected at the end of the 4 hr session in order to prevent artificially 
influencing drinking behavior by causing undue stress during the drinking session. Thus we 
speculate that if tailblood samples were collected at 2 hr into the final test session, the BECs 
achieved would closely reflect the drinking behavior, with MTII-treated mice displaying blunted 
BECs relative to vehicle-treated mice. Interestingly, bilateral infusion of MTII into the LH did 
not significantly affect intake of a 10% sucrose solution under an identical DID protocol. This 
finding was surprising in light of the fact that both the melanocortin system (Fan et al, 1997) as 
well as the LH (Anand et al, 1951) have been extensively associated with feeding behavior. 
However, in Chapter 2 we saw that repeated cycles of binge-like ethanol intake, but not binge-
like sucrose intake, were associated with a decrease in immunoreactivity of the endogenous 
melanocortin agonist α-MSH. These data provide further evidence that melanocortin signaling 
within the lateral hypothalamus is not strictly responsible for regulating general consummatory 
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behavior but is part of a larger network involved in regulating the neurobiological responses to 
rewarding substances, including ethanol.  
Interestingly, administration of the selective MC4R agonist significantly reduced both 
ethanol and sucrose consumption during the first half of the drinking session, as well as both 
sucrose consumption and BECs achieved over the entire 4 hr session.  These data are not 
particularly surprising, given the divergent roles of MC3R and MC4R in feeding behavior and 
ethanol intake.  Indeed, previous work has indicated that the effect of the nonselective 
melanocortin agonist MTII on food intake (Kumar et al, 2009) and ethanol intake (Navarro et al, 
2005) is mediated by MC4R, not MC3R. Further, it has been shown that the MC3R functions in 
opposition to the MC4R in regards to feeding behavior.  While selective MC4R agonism has 
been shown to blunt ethanol (Navarro et al, 2005) and food intake (Kievit et al, 2012), 
administration of the selective MC3R agonist D-Trp8-γ-MSH in both rats (Lee et al, 2008)  and 
mice (Marks et al, 2006) has been shown to stimulate food intake, while antagonism of this 
receptor via the selective MC3R agonist PG-932 has been shown to decrease feeding behavior 
(Lee et al, 2008).  Indeed, evidence suggests that the MC3R may act as a neuromodulatory brake 
on MC4R receptor function (Renquist et al, 2011).  As MTII is an extremely potent nonselective 
melanocortin agonist with activity at both the MC3R and MC4R (Haskell-Luevano et al, 1997; 
Schioth et al, 1997), it is possible that administration of MTII into the LH reduced ethanol 
drinking behavior via the MC4R and the lack of an effect of MTII on sucrose drinking may have 
resulted from the counteracting effect of the MC3R on MC4R activation; that is, activation of 
MC3R negated the effects of MC4R activation on sucrose drinking. It should be noted that this 
explanation for MTII’s selective effect on ethanol drinking but a non-selective effect of the 
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MC4R agonist on ethanol and sucrose drinking makes the assumption that the MC3R does not 
play a critical role in ethanol drinking, an observation supported by our previous data (Navarro et 
al., 2005).  
Intra-LH infusion of AgRP, a nonselective melanocortin antagonist, was sufficient to 
augment levels of binge-like ethanol consumption above that observed in vehicle-treated mice, 
although a significant change in BECs was not detected. This increase in ethanol intake was 
particularly interesting given the high levels of consumption observed in vehicle-treated mice, as 
it may have been expected that AgRP would be unable to significantly augment ethanol drinking 
due to a ceiling effect. These data strongly suggest a role for endogenous melanocortin signaling 
in modulating excessive ethanol intake, as blockade of this signaling was sufficient to 
significantly impact voluntary ethanol consumption.   
Given the robust effects observed within the LH, we surgically implanted bilateral 
cannulae into the BNST of a separate group of mice. This region was chosen as a control site to 
examine the site-specificity of the aforementioned LH effects as previous work demonstrated 
that the BNST displays robust levels of endogenous melanocortin peptides that do not appear 
significantly impacted by a history of binge-like ethanol consumption (Chapter 2).  Surprisingly, 
administration of MTII into this region caused a significant decrease in ethanol, but not sucrose, 
drinking. However, antagonism of melanocortin signaling by AgRP had no effect on ethanol 
consumption. As superphysiological levels of melanocortin agonism, but not blockade of 
endogenous signaling, affected behavior, we believe that endogenous melanocortin signaling 
within the BNST is not a key modulator of binge-like ethanol drinking. These data also suggest 
that LH is particularly important in controlling binge-like drinking, as pharmacological 
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manipulation of melanocortin signaling in this region was sufficient to bidirectionally influence 
this behavior. 
Melanocortin receptors are found within a number of brain regions thought to mediate 
drug reward (Alvaro et al, 1997), and manipulation of this neuropeptide system has been shown 
to alter neuronal activity in critical regions of the mesolimbic dopaminergic pathway, a well-
studied network responsible for mediating the rewarding effect of drugs (Lindblom et al, 2002a; 
Lindblom et al, 2001). Evidence also suggests that interactions between endogenous 
melanocortin and opioidergic signaling within this pathway may be important for ethanol 
drinking behavior (Ploj et al, 2002). Further, opioids in the perifornical lateral hypothalamus 
have recently been shown to play a particular role in suppressing voluntary ethanol intake in rats, 
with no effect on either food or water intake (Chen et al, 2013). This suppressive effect has been 
suggested to be mediated by interactions with local neuronal populations, including orexin. 
Opioids have previously been shown to have an inhibitory effect on orexin neurons within the 
LH (Georgescu et al, 2003), and hypothalamic injection of orexin has been found to enhance 
ethanol intake in Sprague-Dawley rats (Schneider et al, 2007). Given the known interplay 
between the opioid and melanocortin systems, as well as the suggestion that orexin-expressing 
neurons within the LH may be targets of MC4R LH neurons (Cui et al, 2012), it is possible that 
the effects on ethanol drinking following pharmacological manipulation of the LH melanocortin 
receptors observed in the present study are a result of a complex interaction between these 
neuronal networks. 
An important consideration, given the experimental design of the previously described 
experiments, is that pharmacological manipulation of the LH melanocortin system simply affects 
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all consummatory behaviors. To address this consideration, a separate group of animals with 
indwelling cannulae targeting the LH underwent a modified DID protocol in which identical 
water and ethanol bottles were available during the 2 hr and 4hr testing periods. Animals 
received either MTII or saline prior the test session, and half of the animals had food available 
during the test session.  This experimental setup allowed us to examine not only the role of 
melanocortin agonism via MTII administration on ethanol intake, water intake, ethanol 
preference, and food intake, but also allowed us to explore how access to food during the binge 
test might separately influence fluid consumption. To this end, we present compelling evidence 
that while MTII decreased ethanol and food consumption, the melanocortin agonist did not affect 
water consumption.  Treatment with MTII also reduced ethanol preference, an effect related to 
this decrease in ethanol intake without an associated alteration in water intake. Importantly, these 
data indicate that melanocortin receptor activation does not simply modulate all consummatory 
behavior. Further, we observed a significant effect of food availability during the test session on 
both water intake and ethanol preferences. These data are in accordance with a well-supported 
literature of prandial drinking showing that water intake and food intake are related: in the rat, 
roughly 70% of water intake is temporally associated with food intake (Fitzsimons and Le 
Magnen, 1969; Kissileff, 1969). These data are particularly interesting in light of recent data 
suggesting that a separate neuropeptide system, corticotrophin-releasing factor, may not have 
specific effects on excessive ethanol drinking behavior under the DID protocol, despite previous 
evidence to the contrary; in that study, the impact of food consumption on water intake and the 
resulting effects on ethanol preference were not taken into consideration (Giardino and Ryabinin, 
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2013). Indeed, our results highlight the importance of considering how the availability of food 
during a DID session may indirectly influence ethanol preference via an increase in water intake. 
 In summary, the present data extend the current literature suggesting a role for 
melanocortin signaling, particularly through the MC4R and in the LH, in modulating excessive 
ethanol intake under a binge-like drinking protocol. Further, while melanocortin signaling within 
this region also impacts food consumption, it is possible that the role of this system extends 
beyond simple consummatory behavior and taps into circuits responsible for influencing 
neurobiological responses to salient reinforcers, regardless of caloric content. The next chapter of 
this dissertation will explore the role of ERK signaling as a potential intracellular mechanism 
through which MC4R signaling influences binge-like ethanol drinking. 
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3.1: Schematic of cannulae placements in the LH and BNST. Placements of correct hits from in 
the LH (A) and BNST (B) are shown on representative images from the mouse brain atlas 
(Franklin and Paxinos, 1997). Circles indicate correct cannulae placement; data from these 
animals were included in all analysis. X indicates missed cannulae placement; data from these 
animals were not included in analysis. Arabic numerals indicate distance from Bregma (mm). 
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Figure 3.2: The effects of melanocortin agonism in the LH on binge-like ethanol and sucrose 
consumption and BECs. Melanocortin agonism within the LH lead to a significant decrease in 
binge-like ethanol consumption (A). This effect was most striking during the first hour of the 4 
hr test session, as levels of ethanol drinking in MTII-treated animals did not differ from vehicle-
treated treated animals at the end of the session (B). BECs were not significantly different 
between groups (C), and MTII did not significantly affect binge-like sucrose drinking under a 
similar protocol. All data are shown as mean ± SEM. Significance was accepted at p <0.05; * 
p<0.05.  
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Figure 3.3: The effects of selective MC4R agonism in the LH on binge-like ethanol and sucrose 
consumption and BECs. Melanocortin agonism within the LH using a selective MC4R agonist 
lead to a significant decrease in binge-like sucrose (B), but not ethanol (A) intake. However, 
MC4R agonist treatment decreased both ethanol (C) and sucrose (D) consumption during the 
first two hours of the session, but did not significantly influence any drinking behavior during the 
second half of the session (E, F).  Interestingly, despite only decreasing ethanol consumption 
during the first half of the session, MC4R agonist treatment significantly decreased the total BEC 
achieved over the entire 4 hr test session (G). All data are shown as mean ± SEM. Significance 
was accepted at p <0.05; * p<0.05, **p<0.01. 
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Figure 3.4: The effects of melanocortin antagonism in the LH on binge-like ethanol and sucrose 
consumption and BECs.  Melanocortin antagonism within the LH lead to a significant increase in 
binge-like ethanol consumption (A), although there was not a significant difference in BEC 
achieved over the total 4 hr session (B). Intra-LH infusion of AgRP did not significantly affect 
binge-like sucrose drinking under a similar DID protocol. All data are shown as mean ± SEM. 
Significance was accepted at p <0.05; * p<0.05.  
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Figure 3.5: The effect of melanocortin agonism in the BNST on binge-like ethanol and sucrose 
consumption and BECs. Bilateral intra-BNST infusion of MTII lead to a significant decrease in 
binge-like ethanol consumption (A) but did not significantly affect the total BEC achieved over 
the 4 hr binge-like drinking session (B).  As seen in the LH, despite decreasing ethanol 
consumption, MTII administration did not significantly affect binge-like sucrose consumption. 
All data are shown as mean ± SEM. Significance was accepted at p <0.05; * p<0.05.  
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Figure 3.6: The effect of melanocortin antagonism in the BNST on binge-like ethanol 
consumption and BECs. Bilateral intra-BNST infusion of AgRP did not significantly affect 
binge-like ethanol drinking (A). There was also no between-groups difference in BEC achieved 
following 4 hr ethanol drinking. All data are shown as mean ± SEM, and significance was 
accepted at p <0.05. 
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Figure 3.7: Ethanol and water intake in a two-bottle choice DID following intra-LH infusion of 
the melanocortin agonist MTII. Half of the animals in each drug group also had food available 
during the final binge test, while the other half of the animals did not did not have any food 
available.  While MTII reduced ethanol consumption regardless of food availability (A), the 
presence of food impacted water consumption regardless of drug treatment (B). There was a 
main effect of both food availability and drug treatment on ethanol preference, although there 
was not a significant interaction between variables, on ethanol preference over the 4 hr period 
(C). Neither drug treatment nor food availability affected BEC achieved (D). MTII-treated 
animals also displayed blunted food intake over the 4 hr period relative to saline-treated animals 
(E). All data are shown as mean ± SEM, and significance was accepted at p<0.05; 
*p<.05;**p<0.001 
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Figure 3.8: Ethanol and water consumption and ethanol preference analyzed during the first and 
second halves of the binge test. Half of the animals in each drug group also had food available 
during the final binge test, while the other half of the animals did not.  MTII reduced ethanol 
consumption during the first half of the drinking session, regardless of food availability (A), but 
did not affect ethanol intake during the second half of the session (B). Conversely, the presence 
of food in the cage did not influence water consumption during the first half of the binge test (C), 
but significantly increased water consumption during the second half of the session independent 
of drug treatment (D). Additionally, the availability of food decreased ethanol preference during 
the second half (F) but not the first half (E) of the final binge test, an effect not related to MTII 
treatment. All data are shown as mean ± SEM, and significance was accepted at p <0.05; 
**p<0.001. 
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CHAPTER 4 
 
THE EFFECTS OF SITE-DIRECTED INHIBITION OF ERK SIGNALING ON  
BINGE-LIKE ETHANOL CONSUMPTION 
 
 
Introduction 
The melanocortin system encompasses a complex network that has long been known to 
modulate various aspects of feeding behavior and energy homeostasis (Nahon, 2006) in both 
human (Calton et al, 2009; Vaisse et al, 2000) and rodent (Davis et al, 2011; Huszar et al, 1997; 
Marsh et al, 1999) populations. Additionally, a growing body of literature suggests that this 
neuropeptide system is both affected by ethanol exposure and may modulate ethanol-drinking 
behaviors (Navarro et al, 2005; Ploj et al, 2002), including binge-like ethanol drinking (Chapters 
2-3). This pattern of excessive ethanol consumption, associated with a variety of health risks and 
linked with the development of alcohol dependence (Courtney et al, 2009; Hingson et al, 2006a; 
Miller et al, 2007), has recently been modeled in animals using the “drinking in the dark,” or 
DID, protocol (Rhodes et al, 2005). This model, which capitalizes on the innate consummatory 
patterns of mice, reliably generates high levels of voluntary ethanol consumption and has been 
well established as model of human binge ethanol drinking (Sprow et al, 2012). 
The melanocortin system consists of an elaborate network of heterotrimeric G-protein-
coupled receptors (MC1R-MC5R) with distinct central and peripheral distributions (Hadley et al, 
1999). While MC1R, MC2R, and MC5R are mainly distributed to varying degrees in the 
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periphery, MC3R and MC4R are the most predominant receptor subtypes expressed in the rodent 
brain, with MC3R having a more limited distribution than MC4R (Mountjoy et al, 1994). These 
receptors are acted upon by several bioavailable neuropeptides. Indeed, the endogenous 
melanocortin agonist α-melanocycte stimulating hormone (α-MSH) is cleaved from the 
polypeptide precursor pro-opiomelanocortin (POMC) and is found in neurons emanating from 
the arcuate nucleus of the hypothalamus (Jacobowitz et al, 1978; O'Donohue et al, 1979). While 
melanocortin receptors are found throughout most regions of the brain, they are predominantly 
expressed within hypothalamic nuclei.  This system is also somewhat unique in that it contains 
an endogenous melanocortin receptor antagonist, agouti-related protein (AgRP), a protein that is 
expressed in GABAergic neurons that largely overlap in their expression with POMC-expressing 
neurons (Hahn et al, 1998). Indeed, AgRP neurons directly inhibit POMC neurons, and the 
integration of these orexigenic (AgRP) and anorexigenic (α-MSH) signals plays a key role in 
modulating energy expenditure and caloric intake (Cowley et al, 1999; Mul et al, 2012). 
Additionally, while both MC3R and MC4R have been implicated in similar physiological 
processes, they appear to have complementary rather than directly overlapping functions: for 
example, while both MC3R and MC4R may regulate body weight, the MC4R in particular is 
implicated in appetite regulation. 
Although the melanocortin system is implicated in modulating a wide variety of 
behaviors and physiological processes, the intracellular signaling pathways through which the 
melanocortin receptors exert their effects remain unclear.  Agonist binding at both MC3R and 
MC4R, Gs-linked G-protein coupled receptors, has been shown to activate adenylyl cyclase, 
which leads to an increase in cyclic AMP (cAMP) and in turn an increase in protein kinase A 
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(PKA) production (Gantz et al, 1993; Mul et al, 2012). Indeed, PKA activation via alteration of 
the RIIβ subunit has been shown to reduce the obesity syndrome of agouti lethal yellow mice 
that have a genetic rearrangement of the agouti locus (Czyzyk et al, 2008). These data suggest 
that agouti antagonism of MC4R in the hypothalamus requires normal functioning of PKA 
signaling. In vitro work has also indicated that activations of the cAMP-PKA pathway via MC4R 
agonism in particular can induce expression of brain-derived neurotrophic factor (BDNF) 
(Caruso et al, 2012). These data indicate that agonism of the MC4R operates, at least in part, 
through activation of the cAMP-PKA pathway. 
In addition to a bounty of work examining the role of PKA signaling related to 
melanocortin receptor activation, a growing literature has indicated that agonism at both MC3R 
and MC4R also relies on the activation of other intracellular mechanisms, some of which occur 
independently of PKA signaling. For example, activation of the MC4R with the potent 
melanocortin agonist MTII dose-dependently increased phosphorylation of key components of 
the mitogen-activated protein kinase (MAPK) pathway, the transcription factors extracellular 
signal related protein kinase 1 and 2 (ERK1/2), as well as cAMP response element-binding 
protein, or CREB (Sutton et al, 2005). HEK 293 cells expressing the MC3R, when exposed to a 
separate melanocortin receptor agonist, also showed a dose-dependent increase in 
phosphorylation at these markers, an effect that was blocked by administration of a melanocortin 
antagonist (Chai et al, 2007). These data indicate that ERK signaling may be a particularly 
important signaling pathway through which the melanocortin system can exert its 
neurobiological effects. 
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While the cAMP-PKA cascade can directly influence ERK1/2 signaling, recent in vitro 
evidence has suggested a role for melanocortin-induced ERK signaling independent of PKA. In 
COS-1 cells that were transfected with either MC3R or MC4R, for example, the formation of 
cAMP was always observed (Daniels et al, 2003). However, this study indicated that the ERK 
signaling cascade was coupled specifically to the MC4R, and not the MC3R.  Further, Sutton and 
colleagues showed that treatment with the MEK inhibitor U0126, which serves as an inhibitor of 
downstream ERK signaling, both attenuated MTII-induced ERK phosphorylation in the rat 
solitary nucleus as well as blocked the expected MTII-induced suppression of food intake 
(Sutton et al, 2005). In the same study, MTII-induced ERK phosphorylation was blunted, but not 
completely blocked, by treatment with the cAMP inhibitor cAMPS-Rp.  These data suggest that 
while the cAMP-PKA pathway contributes to the activation of the ERK signaling pathway 
initiated by activation of melanocortin receptors, it is likely that melanocortin agonism may also 
induce neurobiological effects through PKA-independent activation of ERK signaling. 
 The present experiments were designed to assess the role of ERK signaling within the 
lateral hypothalamus (LH) in modulating the reduction of binge-like ethanol drinking following 
site-directed agonism of the melanocortin system within this region. To this end, we first 
determined an appropriate dose of the potent MEK inhibitor U0126 that would block ERK 
signaling without having an intrinsic effect on ethanol drinking behavior. Next, a separate group 
of mice implanted with bilateral cannulae targeting the LH received a bilateral infusion of either 
U0126 or vehicle shortly before an infusion of the melanocortin agonist MTII (or saline). Here, 
we found that although administration of U0126 alone did not significantly affect binge-like 
ethanol drinking behavior, infusion of the same dose of this compound blunted the anticipated 
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MTII-induced decrease in binge-like ethanol consumption. These observations suggest that ERK 
signaling induced via activation of the lateral hypothalamic MC4R is at least partially 
responsible for modulating the reduction of binge-like ethanol intake observed following MTII 
administration within this region.  
Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratories) were 6-8 weeks of age and weighed approximately 
23 g at the beginning of each experiment. Mice were individually housed in polypropylene cages 
with corncob bedding and allowed to habituate to the environment for one week prior to study 
initiation. Animals had ad libitum access to food and water, except where noted below, and were 
evenly distributed between two animal colonies. Both animal colonies were maintained at 
approximately 22° Celsius with a 12h:12h light:dark cycle (lights off at 7 a.m. (A) or 10 a.m. 
(B)). All procedures and protocols used in the present study were in accordance with National 
Institute of Heath guidelines and were approved by the University of North Carolina Institutional 
Animal Care and Use Committee.  
Drugs 
Ethanol (20%, v/v) solutions for consumption during DID testing were prepared using tap water 
and 95% ethyl alcohol (Decon Laboratories Inc., King of Prussia, PA). The MEK inhibitor 
U0126 (Tocris Biosciences, Minneapolis, MN) was dissolved in a vehicle containing 5% DMSO, 
6% Tween-80, and 89% 0.1 M PBS to reach the appropriate concentration (0.0, 0.25, 0.50, 1.00, 
1.50, 2.0, 2.5, 3.0, 3.5, or 4.0 nmol/0.5 µl). Experiment 1 was designed to determine the highest 
dose of U0126 that did not have an effect on behavior: mice were bilaterally infused with 0.5 µl 
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of U0126 at the appropriate concentration over a period of 1 min. In Experiment 2, 2.0 nmol/ 0.5 
µl/side was infused 15 min prior to infusion of the nonselective melanocortin receptor agonist 
melanotan II (MTII; 0.5 nmol/0.25 μl/side; American Peptide, Sunnyvale, CA). MTII was 
dissolved in sterile saline. The dose chosen was based on previously published work from our 
laboratory and others (Navarro et al, 2005; Ploj et al, 2002), as well as data from Chapter 3 of 
this dissertation showing that this dose is effective at reducing binge-like ethanol drinking in 
C57BL/6J mice when bilaterally infused into the LH. 
Drinking in the Dark (DID) Procedures  
Animals underwent a 4-day DID procedure previously used in our laboratory (Lowery et al, 
2010; Navarro et al, 2009; Sparta et al, 2008) to model binge-like ethanol consumption. Briefly, 
on days 1-3, water bottles were removed from cages 3 hr into the dark cycle.  Bottles containing 
20% (v/v) ethanol were placed on the home cage and secured in place. Fluid levels were 
immediately measured to the nearest 0.1 mL. Changes in fluid level were monitored hourly; after 
the 2 hr measurement, the bottles were removed from the cages and the original water bottles 
were replaced on the cages. Mice were left undisturbed until the next day. Immediately before 
ethanol bottle presentation on the fourth day, mice received a bilateral infusion of the appropriate 
drug(s). On this day, ethanol access was extended to 4 hr; all other procedures were identical to 
days 1-3. The amount of ethanol consumed during each hour of the 4 hr binge test, as well as the 
total amount consumed over the entire 4 hr period, was calculated and is expressed as grams of 
ethanol per kilogram of body weight (g/kg). 
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BECs 
To assess blood ethanol concentrations (BECs), a small nick was made at the tip of the tail and 
approximately 10-15μl of blood was collected in heparinized capillary tubes (Fisher Scientific, 
Pittsburgh, PA). Blood samples were centrifuged to separate the plasma from the blood and 5μl 
of the plasma was analyzed using the Analox Blood Analyzer (Analox Instruments USA, 
Lunenburg, MA). Data is reported as mg/dl. 
Surgery and Microinfusion Procedures  
Approximately 2 weeks after arrival, mice were anesthetized with a cocktail of ketamine (117 
mg/kg) and xylazine (7.92 mg/kg) and implanted with bilateral 26-gauge cannulae (Plastic One, 
Roanoake, VA) aimed at the lateral hypothalamus (LH; 1.1 mm posterior to bregma, 1.1 mm 
lateral to the midline, and 5.1 mm ventral to the skull surface) using procedures commonly used 
in our laboratory (Lowery et al, 2010; Sparrow et al, 2012). Mice were allowed to recover for a 
minimum of one week before the initiation of experimental procedures. All cannulae placement 
was verified histologically at the end of the experimental procedures, and any animals with 
unilateral or bilateral misses were excluded from all data (n = 6) analyses. The site-directed 
infusions were delivered in a 0.5 μl volume over a 1 min period  (U0126) or a 0.25 μl volume 
over a 30 sec period (MTII) using a using a 1.0 μl Hamilton microsyringe controlled by a 
Harvard Apparatus PHD 2000 microinfusion pump. In Experiment 2, infusions were separated 
by 15 min and ethanol was presented immediately after the second infusion. Injectors were left in 
place for 1 min after each infusion in order to ensure drug diffusion. Mice were habituated to the 
infusion procedure 2-4 times before the initiation of the DID cycle.  
Experimental Protocol 
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Experiment 1: U0126 and binge-like ethanol drinking (dose response)  
 The overarching goal of the present set of experiments was to determine if the blunting of 
excessive ethanol intake following intra-LH infusion of MTII is mediated by ERK signaling 
within this region.  Thus the goal of Experiment 1 was to determine the highest dose of the 
MEK inhibitor U0126, which inhibits downstream ERK signaling, that did not have an 
independent effect on binge-like ethanol intake in order determine the appropriate sub-threshold 
dose that should be used to block the effect of MTII. To this end, mice (n = 47) were surgically 
implanted with bilateral cannulae targeting the lateral hypothalamus. Mice were allowed to 
recover from surgery for at least one week before the initiation of experimental procedures.  
Experiment 1A:  U0126 and binge-like ethanol drinking (lowest doses) 
Approximately 30 min prior to ethanol presentation on day 4 of the DID cycle, mice received 
an infusion of vehicle, 0.25, 0.50, or 1.0 nmol U0126. Drug doses were assigned based on 
average ethanol drinking on day 3 of the DID cycle. Ethanol consumption was measured hourly 
for the 4 hr binge test, and tailblood samples were collected for BEC analysis immediately after 
bottles were removed at the end of the test session. 
Experiment 1B:  U0126 and binge-like ethanol drinking (highest doses) 
As none of the doses of U0126 examined in Experiment 1A had a significant effect on 
excessive ethanol drinking, mice experienced a second cycle of binge-like ethanol drinking after 
at least three days of rest, during which they had ad libitum access to only food and water. For 
this DID cycle, mice received an infusion of vehicle, 2.5, 3.0, 3.5, or 4.0 nmol U0126 in a 
procedure identical to that described above. Drug doses were counterbalanced based on ethanol 
drinking on day 3 as well as previous drug history. 
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Experiment 1C:  U0126 and binge-like ethanol drinking (mid-range doses) 
Although a one-way ANOVA of the entire dose range from Experiment 1B did not reveal 
a significant effect of U0126 on ethanol drinking, planned comparisons revealed that the 2.5 
nmol dose of U0126 significantly elevated ethanol drinking relative to vehicle-treated mice. To 
confirm this increase, mice experienced a third cycle of DID after at least three days of rest, 
during which they had access to ad libitum food and water. In this final round, mice received 
vehicle, 1.5, 2.0, or 2.5 nmol U0126, counterbalanced based on ethanol drinking behavior and 
previous drug history. All procedures were identical to those described above.  At the end of 
Experiment 1C, all mice were sacrificed and cannulae placement was verified histologically.  
Experiment 2: The effect of pre-treatment with a MEK inhibitor on MTII-induced blunting of 
binge-like ethanol drinking  
 The goal of Experiment 2 was to examine whether the blunting of excessive ethanol 
intake induced by intra-LH MTII administration, as observed in Chapter 2, is mediated by ERK 
signaling. To this end, a separate group of mice (n = 48) was surgically implanted with bilateral 
cannulae targeting the LH. Mice were allowed to recover for at least one week before the 
initiation of a DID cycle. On day 4 of the DID cycle, mice received a bilateral intra-LH infusion 
of either vehicle or U0126 (2.0 nmol/0.5 µl/side).  Approximately 15 minutes later, mice 
received a bilateral inra-LH infusion of either saline or MTII (0.5 nmol/0.25 µl/side).  Ethanol 
was presented immediately following the second infusion, and fluid displacement was measured 
hourly for the 4 hr binge test. Following two weeks of rest, during which mice received ad 
libitum food and water access, these mice were used in a separate study examining the effect of 
84 
 
intra-LH MTII infusion on ethanol preference and food consumption (see Chapter 2). At the end 
of all experimentation, mice were sacrificed and cannulae placement was verified histologically.  
Data Analysis 
As the mice in Experiment 1 were housed in two separate colony rooms, ANOVAs were used to 
determine whether there was a significant colony room by drug treatment interaction. In the case 
of no interaction, data were collapsed across rooms. Given an interaction of these variables in 
Experiment 1C, data from this experiment were analyzed separately by colony room. One-way 
ANOVAs were used to assess the effect of drug dose on ethanol consumption and BECs. For 
Experiment 2, a 2 x 2 ANOVA was performed in order to assess the interaction between drug 
pretreatment (vehicle vs. U0126) and drug (saline vs. MTII) on ethanol drinking, BEC, and food 
consumption. In accordance with planned comparisons and in order to directly compare the four 
treatment groups (Veh-Sal, Veh-MTII, U0126-Sal, U0126-MTII), a one-way ANOVA was used 
to examine between-groups differences in ethanol drinking, BEC achieved, and food 
consumption. Specific differences were examined using LSD post-hoc tests. All data is presented 
as mean ± SEM, and significance was accepted at p<0.05 (two-tailed). Only animals with 
bilateral cannulae targeting either the LH were included in any data analysis described herein 
(n=92, 10-12/group). Additionally, in several cases an ethanol bottle leaked during the test 
session and the animal was removed from analysis for that segment, accounting for differences 
in degrees of freedom between identical analyses. Finally, in several cases a tailblood sample 
was immeasurable and thus excluded from the analysis, also accounting for differences in 
degrees of freedom between identical analyses.  
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Results 
 All mice in Experiments 1-2 were surgically implanted with bilateral cannulae targeting 
the lateral hypothalamus (LH). Figure 4.1 shows the approximate location of the cannulae 
placements for bilateral hits in Experiment 1 (Figure 4.1A) and Experiment 2 (Figure 4.1B).  
Experiment 1A: U0126 dose response (lowest doses) 
 The effect of the MEK inhibitor U0126 (0.25, 0.50, 1.00, or 1.50 nmol) on binge-like 
ethanol drinking is shown in Figure 4.2. As there was not a significant interaction between 
colony room and drug treatment (F(4,31)=0.319, p=0.863), data were collapsed across rooms. 
Figure 4.2A shows that there was no effect of drug treatment on ethanol consumption over the 
entire 4 hr binge period (F(4,36)=1.671, p=0.178). As we have previously shown that the 
strongest effect of site-directed pharmacological manipulation tends to occur within the first half 
(2 hr) of the binge session (Chapter 2), we also examined ethanol intake over this period. No 
dose of U0126 had a significant effect on excessive ethanol consumption during the first half of 
the session (F(4,36)=1.470, p=0.232; Figure 4.2B). Further, there was no significant effect of 
any low dose of the MEK inhibitor on the BEC achieved over the 4 hr binge test (F(4,36)=0.319, 
p=0.863). 
Experiment 1B: U0126 dose response (highest doses) 
 As there was no effect of the first range of U0126 doses (Experiment 1A) on binge-like 
ethanol consumption, mice next received 2.5, 3.0, 3.5, or 4.0 nmol U0126 or vehicle prior to 
ethanol access on the final day of an additional DID cycle. The effect of this dose range on 
excessive ethanol consumption is shown in Figure 4.3. As there was not a significant interaction 
between colony room and drug treatment (F(4,29)=0.448, p=0.773), drinking data were 
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collapsed across rooms. One-way ANOVA of these data show that there was not a significant 
effect of drug dose on ethanol consumption during the 4 hr (F(4,34)=1.220, p=0.321) or 2 hr 
(F(4,34)=0.674, p=0.615) period. As previous literature has shown that doses comparable to the 
lowest dose tested in this dose response curve are sufficient to alter behavior (Miller and 
Marshall, 2005), and a priori hypotheses anticipated that this dose would have a significant 
effect on altering binge-like drinking behavior, the difference in ethanol intake between the 
vehicle group and 2.5 nmol group was assessed using a t-test. This analysis revealed a significant 
difference between groups (t(13)=-2.266, p=0.041) at the 4 hr, but not 2hr (t(13)=-0.763, 
p=0.459) time point. Further, there was not a significant effect of U0126 on BECs achieved over 
the 4 hr period (F(4,34)=1.433, p=0.224).  
Experiment 1C: U0126 dose response (mid-range doses) 
 As analysis of the previous range of doses indicated a significant effect of the 2.5 nmol 
dose of U016 on excessive ethanol intake, we infused mice with a third range of U0126 doses in 
order to confirm the highest dose of U0126 that did not have an effect on ethanol drinking. As 
analysis indicated that there was a significant interaction between colony room and drug 
treatment regarding ethanol intake over the 4 hr period (F(3,34)=4.507, p=0.009), data for this 
experiment were analyzed separately for each colony room. Ethanol drinking over the 4 hr 
period, the first half of session, and BEC achieved over the 4 hr session are shown for colony A 
(Figure 4.4A, 4.4C, and 4.4E) and colony B (Figure 4.4B, 4.4D, and 4.4F). There was not a 
significant effect of any dose of U0126 on 4 hr consumption (F(3,17)=1.878, p=0.172), 2 hr 
consumption (F(3,17)=0.660, p=0.588), or BEC achieved (F(3,17)=0.197, p=0.897) in colony A. 
In contrast, there was a significant effect of the highest dose (2.5 nmol) of U0126 on 4 hr 
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consumption (F(3,17)=4.177, p=0.022) and BEC achieved (F(3,17)=3.752, p=0.031), but not 2 
hr ethanol consumption (F(3,17)=1.044, p=0.399) in mice from colony room B. Post-hoc tests 
indicated that 2.5 nmol U0126 significantly augmented ethanol intake relative to both vehicle 
and 1.5 nmol groups, although the BEC was only significantly augmented relative to the vehicle-
treated group.  
Experiment 2: MEK inhibition blocks the effect of MTII on binge-like ethanol drinking. 
 The goal of Experiment 2 was to determine if the blunting of excessive ethanol intake 
induced by microinfusion of MTII into the LH is mediated through ERK signaling. To this end, 
we administered the highest dose of the potent MEK inhibitor U0126 (or vehicle) that did not 
have an effect on ethanol intake alone approximately 15 min prior to administration of MTII (or 
saline). The dose of MTII used has previously been shown to blunt excessive binge-like ethanol 
intake when administered into the LH prior to ethanol presentation (Chapters 2-3). The effects of 
these drug treatments on 4 hr (A), and 2 hr ethanol consumption (B), as well as BEC achieved 
(C) and total food consumption (D), are shown in Figure 4.5. There was not a significant 
interaction between pretreatment (U0126 or vehicle) and treatment (MTII or saline) on 4 hr 
ethanol consumption (F(1,41)=0.008 p=0.929), although there was a significant main effect of 
both pretreatment (F(1,41)=6.607, p=0.014) and  treatment (F(1,41)=19.101, p=0.000). To 
further examine between-group differences, a one-way ANOVA was performed on the four 
groups of animals (Veh-Sal, Veh-MTII, U0126-Sal, U0126-MTII; Figure 4.5A). This analysis 
confirmed a significant effect of group on 4 hr ethanol consumption (F(3,41)=8.101, p=0.000). 
Post-hoc tests indicated that while Veh-MTII mice displayed blunted 4 hr ethanol intake relative 
to both saline-treated groups, U0126-MTII-treated mice did not show decreased intake relative to 
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Veh-Sal mice. Importantly, mice that received U0126 pretreatment prior to bilateral infusion of 
saline did not differ from mice that received vehicle pretreatment prior to saline administration, 
although these U0126-Sal mice did show significantly augmented ethanol intake relative to both 
MTII-treated groups. These data indicate that pretreatment with the MEK inhibitor U0126 
attenuated the reduction of binge-like ethanol intake typically observed over the 4 hr period 
following bilateral intra-LH infusion of MTII. 
 In regards to drinking specifically during the first half of the binge test, there was again 
no interaction between drug pretreatment and drug treatment (F(1,41)=0.292, p=0.592), although 
there were significant main effects of both pretreatment (F(1,41)=4.760, p=0.035) and drug 
treatment (F(1,41)=23.051, p=0.000). A closer analysis confirmed a significant between-groups 
difference in 2 hr ethanol consumption (F(3,41)=0.000; Figure 4.5B), with post hoc analyses 
indicating that Veh-MTII mice displayed significantly blunted ethanol consumption relative to 
both saline-treated mice, as well as a trend toward a difference from U0126-MTII mice 
(p=0.058).  U0126-MTII mice did not show significantly blunted drinking relative to Veh-Sal 
mice, although they displayed lower levels of intake than U0126-Sal mice. Saline-treated mice 
that were pretreated with a bilateral infusion of U0126 did not show significantly augmented 
drinking relative to Veh-Sal mice. These data show that pretreatment with the MEK inhibitor 
U0126 attenuated the reduction of binge-like ethanol intake observed in the 2 hr immediately 
following bilateral intra-LH infusion of MTII. 
 There was no pretreatment by treatment interaction (F(1,40)=0.581, p=0.450), nor main 
effect of pretreatment (F(1,40)=1.009, p=0.321) or drug treatment (F(1,40)=0.920 p=0.343) on 
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BEC achieved over the 4 hr period (Figure 4.5C). As none of these tests reached significance, 
no further analysis of between-groups difference in BEC was conducted.  
 The effects of U0126 and MTII treatments on food consumption over the entire 4 hr 
session were also examined (Figure 4.5D). While there was not a significant interaction between 
drug pretreatment and treatment (F(1, 41)=1.400, p=0.244) or a significant main effect of drug 
pretreatment on food consumption (F(1,41)=3.757, p=0.059), there was a significant main effect 
of drug treatment (F(1,41)=20.519, p=0.000). A closer analysis of between-groups analysis 
confirmed a between-groups difference in food consumption over the 4 hr period 
(F(3,41)=8.084, p=0.000). While Veh-MTII mice displayed a significant reduction in food intake 
relative to both Veh-Sal and U0126-Sal mice, they did not show a reduction in food intake 
relative to U0126-MTII mice. However, mice pretreated with the MEK inhibitor prior to an 
infusion of saline showed augmented food consumption relative to all other groups; U0126 
pretreated animals later infused with MTII showed a reduction in food consumption only relative 
to the U0126-Sal group, but not to the Veh-Sal group. Similar to the effects observed in ethanol 
drinking behavior, pretreatment with the U0126 blunted the reduction in food consumption 
observed following an intra-LH infusion of MTII. 
Discussion 
 
The present experiments utilized site-directed pharmacological manipulations to 
investigate the role of ERK signaling in the modulation of MTII-induced blunting of ethanol 
intake in an animal model of binge-like ethanol drinking. As previous work (Chapters 2-3) has 
indicated that melanocortin receptor signaling within the lateral hypothalamus (LH) plays a 
particularly important role in modulating binge-like ethanol drinking, mice were surgically 
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implanted with bilateral cannulae targeting this region. Here, we show that while intra-LH 
administration of the potent MEK inhibitor U0126 does not inherently affect ethanol intake, 
pretreatment with this compound is sufficient to blunt the expected reduction of ethanol observed 
following intra-LH MTII administration. These data expand the current literature by indicating 
that melanocortin signaling through MC4R modulates ethanol drinking at least in part via 
recruitment of ERK signaling within the LH. 
The goal of the first series of experiments was two-fold. First, we sought to examine 
whether site-directed infusion of the MEK inhibitor U0126 into the LH would have an effect on 
excessive ethanol drinking under the DID protocol of binge-like ethanol drinking. This 
compound prevents the phosphorylation-dependent activation of ERK (London and Clayton, 
2008), and previous work using this compound has indicated that the decrease in feeding 
behavior observed following ventricular administration of MTII is partially mediated by ERK 
signaling in the solitary nucleus of the rat (Sutton et al, 2005). Second, we wanted to determine 
the highest dose of U0126 that we could administer without having an independent effect on 
ethanol drinking. Thus our overarching goal was to determine a sub-threshold dose of U0126 
that we could use as a pretreatment to block the effect of the melanocortin agonist MTII on 
binge-like ethanol intake.  
The first range of U0126 doses (0.25-1.0 nmol/side) did not have a significant effect on 
binge-like ethanol drinking. All compounds in the present experiments were administered 
immediately prior to the presentation of ethanol. This was done in order to maximize the possible 
effect U0126, which has a half-life of approximately 2 hrs (London et al, 2008). Importantly, the 
stress of the microinfusion procedure did not appear to have a significant effect on ethanol 
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consumption, as levels of ethanol intake in the vehicle group were comparable to previous work 
in which mice were able to recover for an hour or more after drug infusion before being 
presented with ethanol (Chapter 2-3).  
Given the lack of effect of the lower range of doses, all mice underwent a second 
treatment in which they received an infusion of vehicle or a higher dose of U0126 than 
experienced during the first round (2.5-4.0 nmol/side). These doses were counterbalanced based 
on previous drug treatment, and were based on literature showing that higher doses such as these 
have effects on overt behavior (Miller et al, 2005). Importantly, previous in vivo work using 
doses of U0126 similar to those used here been shown to inhibit ERK activity (Miller et al, 2005; 
Sutton et al, 2005). Surprisingly, analysis of the entire range of doses did not indicate an effect of 
U0126 treatment on ethanol intake. However, based on a priori hypotheses as well as the 
possibility that the high levels of ethanol intake induced with this protocol may have yielded a 
ceiling effect, thereby prohibiting a measureable effect of higher drug doses, the ethanol intake 
between vehicle-treated mice and those tested with the lowest dose (2.5 nmol) were compared. 
Interestingly, analysis indicated that this dose of U0126 significantly increased ethanol drinking 
relative to vehicle, although higher doses did not cause any further increase. These data suggest 
that inhibition of ERK signaling is sufficient to significantly augment ethanol intake. 
As the previous DID cycle indicated that treatment with 2.5 nmol of U0126 in the LH 
was able to enhance ethanol intake, animals underwent a final cycle of DID in order to i) confirm 
that this dose has a significant effect on excessive ethanol consumption and ii) clarify the highest 
dose of U0126 that did not have an effect on ethanol drinking. Here, mice received an infusion of 
vehicle or 1.5-2.5 nmol of U0126 immediately prior to ethanol presentation. Although there were 
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different effects of drug administration based on which colony room mice were housed in, an 
effect possibly attributed to unknown environmental disturbances during the testing procedure, 
the effect of the highest tested dose of U0126 was replicated. Given that the 2.5 nmol dose of 
U0126 was sufficient to augment binge-like ethanol drinking, we chose to use the next lowest 
dose tested (2.0 nmol) in order to explore the effect of blocking potential MTII-induced ERK 
signaling on ethanol intake. Thus a separate group of mice received an infusion of U0126 
approximately 15 min prior to an infusion of MTII. These doses were temporally separated in 
order to allow drug diffusion and activation. A similar protocol has previously been used to 
block the effect of MTII on ethanol intake using pretreatment with a melanocortin antagonist 
(Navarro et al, 2003).  
In this experiment, MTII-treated mice that were pretreated with vehicle showed a 
reduction in ethanol intake relative to mice that received treatment of saline following vehicle 
pretreatment. These data confirm earlier findings indicating that melanocortin signaling within 
the LH is important in modulating binge-like ethanol intake. Further, mice pretreated with 
U0126 prior to an infusion of saline did not display significantly altered ethanol intake relative to 
vehicle-saline mice, confirming that this dose of the MEK inhibitor does not have an innate 
effect on ethanol intake. Finally, mice pretreated with U0126 that also received an intra-LH 
infusion of MTII did not show significantly lower ethanol intake relative to vehicle-saline mice, 
indicating that pretreatment with U0126 was sufficient to blunt the expected MTII-induced effect 
on binge-like intake. Interestingly, there was not a significant difference in ethanol consumption 
between the MTII-treated groups, indicating that U0126 only partially blocked the effect of MTII 
on ethanol intake. These data suggest that while ERK signaling is responsible for a substantial 
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portion of the effect of MTII-induced MC4R activation on behavior, this behavior is likely 
mediated, at least in part, by other intracellular signaling mechanisms. These results are 
reminiscent of findings in which the inhibition of ERK signaling reversed MTII-induced feeding 
suppression and attenuated MTII-induced ERK1/2 phosphorylation in the rat solitary nucleus 
(Sutton et al, 2005).  
 The present findings add to a complex literature examining the tangled network of 
signaling pathways coupled with melanocortin receptors, including the MC4R. While numerous 
studies have indicated that the MC4R interacts with Gs-coupled proteins, evidence has also 
indicated that this receptor may activate multiple G proteins and involve a number of interwoven 
signaling pathways. For example, melanocortin-induced activation of ERK1/2 in HEK293 cells 
is susceptible to a Gαi/0-selective inhibitor, although this effect may be somewhat cell-type 
specific (Chai et al, 2006).  Recent work has also suggested that melanocortin-induced PKA-
mediated activation of ERK1/2 is a critical component of α-MSH-induced desphosphorylation of 
AMP-activated protein kinase (Damm et al, 2012), indicating that PKA and ERK signaling 
pathways are directly linked. However, it has also been shown that cAMP is not responsible for 
functional coupling of MC1R to the ERK cascade, but rather that the MC1R activation of cAMP 
and ERK signaling are independent events; indeed, ERK phosphorylation in this study was 
triggered at a much lower agonist concentration than cAMP synthesis, suggesting that activation 
of this receptor produces graded responses to different intracellular signaling mechanisms 
(Herraiz et al, 2009). Investigation of MC3R signaling has also shown mixed results, as reports 
have indicated that activation of the MC3R either does (Begriche et al, 2012; Chai et al, 2007) or 
does not (Daniels et al, 2003) induce ERK signaling. Further, at least one study has indicated 
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that melanocortin-induced activation of ERK1/2 may require PKC, but not PKA, activity (Chai 
et al, 2006). Thus it remains uncertain whether melanocortin-induced activation of PKA and 
ERK1/2 belong to the same or parallel pathways (Breit et al, 2011). As α-MSH agonizes all 
melanocortin receptors, it may be that the degree of the contribution of divergent intracellular 
signaling mechanisms, including ERK1/2 signaling, identify the functional specificity of the five 
melanocortin receptor subtypes.  
 Despite these divergent results, the present data suggest a role for activation of ERK 
signaling in the reduction of ethanol drinking following intra-LH MTII administration. In 
general, ERK signaling is a fundamental component of many intracellular signaling cascades that 
may be positively or negatively coupled to PKA (Adams and Sweatt, 2002), or, as described 
above, may be independent of PKA activity. Indeed, several PKA-independent mechanisms have 
been discovered to activate ERK1/2, including a cAMP-responsive guanidine nucleotide 
exchange factor (de Rooij et al, 1998) as well as a Gi-protein-PI3K signaling system (Chai et al, 
2007). The present data are particularly interesting in light of the litany of behaviors and 
physiological processes attributed to this intricate neuropeptide system. As noted in the 
introduction, the melanocortin system is  associated with energy homeostasis and feeding 
behavior, among a number of other physiological processes (Huszar et al, 1997; Nahon, 2006), 
with more recent evidence suggesting a role for this system in modulating ethanol intake 
(Navarro et al, 2005; Ploj et al, 2002). Many of these behaviors would appear to require long-
lasting, rather than transient, modulation. Intracellular signaling through ERK1/2 pathways is a 
possible mechanism through which melanocortin receptor signaling may modulate such 
behaviors, as this signaling pathway has been shown to directly affect gene expression. Indeed, 
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ERK1/2 has been shown to phosphorylate a number of transcription factors and is a key player in 
the induction of neuronal plasticity (Impey et al, 1999). It is tempting to speculate that agonism 
of melanocortin receptors, including MC4R, induce changes in homeostatic processes as well as 
consummatory behaviors via long-term changes in gene expression. This is supported, for 
example, by long-term suppression of food intake (Fan et al, 1997; Thiele et al, 1998), as well as 
lasting attenuation of ethanol consumption (Navarro et al, 2003) following ventricular 
administration of MTII, behaviors that persist well beyond the time expected given the half life 
of this compound (Ugwu et al, 1994). Indeed, melanocortin signaling has been shown to 
modulate a number of genes that have been implicated in modulating neurobiological responses 
to ethanol. For example, ventricular administration of the melanocortin antagonist AgRP, as well 
as the MC4R-selective antagonist SHU9119, has been shown to augment melanin-concentrating 
hormone (MCH) gene expression in the PVN (Hanada et al, 2000). MCH has been suggested to 
modulate the consumption of rewarding substances, including ethanol; indeed, while intra-PVN 
MCH stimulates ethanol intake, intra-LH MCH has been shown to reduce ethanol intake 
(Morganstern et al, 2010).  Central administration of α-MSH has also been shown to decrease 
orexin mRNA (Hanada et al, 2000); intra-LH injections of orexin have been shown elsewhere to 
stimulate voluntary ethanol intake, without altering consumption of water or food, in Sprague-
Dawley rats (Schneider et al, 2007).  Further, MC4R signaling has been shown to regulate 
energy balance through modulation of the downstream effector brain-derived neurotrophic factor 
(BNDF) (Xu et al, 2003), a neurotrophin that has been linked with the development of alcohol 
dependence (Davis, 2008; Zanardini et al, 2011).  Finally, evidence has suggested that α-MSH 
administration reverses the suppressive effect of fasting on corticotrophin-releasing hormone 
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(CRH) gene expression within the PVN. (Fekete et al, 2000): a growing literature has indicated 
that this peptide may be particularly important in modulating binge-like drinking behavior 
(Lowery-Gionta et al, 2012). Together, these data suggest that melanocortin receptor signaling 
plays an important role in controlling the expression of a diverse array of genes that may in turn 
affect ethanol intake. 
In sum, the current data further implicate the MC4R as a particularly important receptor 
involved in the modulation of binge-like ethanol drinking. Previous work has indicated that ERK 
signaling is coupled with MC4R, but not MC3R, and MTII agonism-induced blunting of ethanol 
intake is attenuated by ERK inhibition.  Further, these data expand the current literature by 
supporting a particular role for ERK signaling pathways coupled to MC4R within the LH as a 
potential mechanism for melanocortin modulation of ethanol intake. Given the present data 
showing that inhibition of ERK signaling within this region is sufficient to blunt binge-like 
ethanol intake, future work is needed to examine downstream targets of ERK1/2. Such 
investigations may thus prove beneficial in the development of novel therapeutic targets for the 
treatment of alcoholism. 
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Figure 4.1: Schematic representation of bilateral cannulae implanted in the LH. Placements of 
correct hits from Experiments 1A-C (A) and Experiment 2 (B) are shown on representative 
schematics from the mouse brain atlas (Franklin et al, 1997). Circles indicate correct cannulae 
placement; data from these animals were included in all analysis. X indicates missed cannulae 
placement; data from these animals were not included in analysis. Arabic numerals indicate 
distance from Bregma (mm). 
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Figure 4.2: The effect of the MEK inhibitor U0126 on binge-like ethanol drinking (low doses). 
Mice were surgically implanted with bilateral cannulae targeting the LH. On the fourth day of 
the DID cycle, mice received a microinfusion of the MEK inhibitor U0126 prior to ethanol 
presentation. Ethanol consumption over the total 4 hr binge test (A) and over the first half of the 
binge test (B) showed no significant effect of MEK inhibition on binge-like ethanol drinking. 
Likewise, there was no significant difference in BEC achieved over the 4 hr session. All data are 
shown as mean ± SEM; significance was accepted at p<0.05. 
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Figure 4.3: The effect of the MEK inhibitor U0126 on binge-like ethanol drinking (high doses). 
As there were no significant differences in ethanol consumption or BEC following treatment 
with the initial doses of U0126, all animals experienced at least 3 days off before undergoing a 
second cycle of DID in which they received a higher dose of the MEK inhibitor. Ethanol 
consumption over the total 4 hr binge test (A) and over the first half of the binge test (B) showed 
no significant effect of MEK inhibition on binge-like ethanol drinking, although a t-test showed 
a significant increase in ethanol intake over the 4 hr session in mice treated with 2.5 nmol U0126 
relative to vehicle-treated mice. Likewise, there were no significant differences in BEC achieved 
over the 4 hr session (C).  All data are shown as mean ± SEM and significance was accepted at 
p<0.05. *p<0.05 
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Figure 4.4: The effect of the MEK inhibitor U0126 on binge-like ethanol drinking (mid-range 
doses). A third cycle of U0126 dose-response testing was performed in order to confirm the 
highest dose of U0126 that did not have an effect on binge-like ethanol intake. Mice in colony 
room A are shown in the left column, and mice in colony room B are shown the right column. 
Although there was no effect of U0126 treatment on ethanol consumption or BEC in animals 
from colony room A (A, C, E), the highest dose of U0126 tested in Colony B significantly 
increased ethanol consumption  over the 4 hr test session relative to vehicle (B) although this 
effect was not apparent in the first half of the session (D). There was a corresponding increase in 
BEC achieved over the test session in animals treated with 2.5 nmol U0126 relative to vehicle-
treated animals (F). All data are shown as mean ± SEM and significance was accepted at p<0.05. 
**p<.0.05 vs. vehicle and 1.5 nmol; * p<0.05 vs. vehicle. 
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Figure 4.5: The effect of pretreatment with the MEK inhibitor U0126 prior to MTII infusion on 
binge-like ethanol drinking. Mice received bilateral intra-LH infusions of vehicle or the MEK 
inhibitor U0126 followed 15 minutes later by saline or the melanocortin agonist MTII.  
Immediately after the second microinfusion, animals were presented with a single bottle 
containing 20% (v/v) ethanol. Infusion of MTII blunted ethanol consumption over the entire 4 hr 
binge test (A), with the most striking effect noted in the first half of the session (B). At both time 
points, this effect was blocked by pre-treatment with the MEK inhibitor U0126. No changes in 
BEC achieved over the 4 hr session were detected (C).  Food consumption over the 4 hr period 
was also reduced, relative to both saline-treated groups, in MTII-treated animals that were 
pretreated with an infusion of vehicle (D). MTII-treated animals pretreated with the MEK 
inhibitor did not show a reduction in food intake relative to saline-treated mice pretreated with 
vehicle. All data are shown as mean ± SEM; significance was accepted at p<0.05. ** different 
from Veh-Sal and U0126-Sal; * different from Veh-MTII and U0126-MTII; # different from 
U0126 only; + different from all other groups  
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CHAPTER 5 
 
GENERAL DISCUSSION 
 
 
 The melanocortin system is well known for playing an important modulatory role in 
feeding behavior (Fan et al, 1997), and recent evidence has suggested that it may also be a key 
player in some, albeit not all, neurobiological responses to ethanol (Navarro et al, 2005; Ploj et 
al, 2002; Sharpe and Low, 2009). Thus the overarching goal of the current dissertation was to 
examine the role that this system may play in controlling binge-like ethanol drinking, a pattern of 
ethanol intake that has repeatedly been linked with the development of ethanol dependence 
(Hingson et al, 2006a; Wechsler et al, 1998). The experiments described in the present 
dissertation took advantage of the “drinking in the dark” (DID) model of binge-like ethanol 
drinking, in combination with immunohistochemical and site-directed pharmacological 
techniques, to examine a) how ethanol affects the expression of key melanocortin components 
and b) how manipulation of this system may alter excessive drinking behavior.  
 To this end, results of the present series of experiments confirmed previous data showing 
that not only does voluntary ethanol consumption differentially affect endogenous melanocortin 
agonists and antagonists, but also that pharmacological manipulation of this system, specifically 
within the lateral hypothalamus (LH), is sufficient to influence associated drinking behaviors. 
Interestingly, these data add to the current literature espousing the LH as an important structure 
for modulating reward-based behavior (Marchant et al, 2012). Together, these novel data provide 
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support for the hypothesis that partially overlapping neural circuitry may be involved in 
modulating neurobiological responses to natural (food) and unnatural (drug) reinforcers. 
Summary of Experimental Findings 
 Using an experimental design in which C57BL/6J mice underwent repeated cycles of 
DID, we observed that mice that experienced one or more cycles of excessive ethanol drinking 
did not show differences in total ethanol consumption or ethanol metabolism, observations that 
have previously been found under a similar protocol (Lowery-Gionta et al, 2012; Sparrow et al, 
2012). As this DID protocol routinely induces high levels of voluntary consumption associated 
with BECs at or above 80 mg/dl (Rhodes et al, 2005), it is possible that the lack of an increase 
here is related to a ceiling effect. Further, although we did not see an increase in binge-like 
drinking over the six weeks of the present study, additional work from our laboratory has 
observed that six or ten cycles of binge-like drinking is associated with a later increase in 
voluntary ethanol consumption and ethanol preference (Cox et al, in press); these adaptations are 
indicative of neuroplastic changes forming as a result of this binge-like ethanol intake. It may 
also be possible that the alterations observed in melanocortin peptides following one or more 
cycles of binge-like drinking behavior are responsible for the perseverance of this excessive 
drinking behavior. These observations are in line with data from the human literature suggesting 
that binge drinking is a particularly persistent pattern of drinking behavior, as adolescents who 
binge drink are more likely than those who do not to continue binge drinking into adulthood 
(Jefferis et al, 2005). Further, it is unlikely that the observed findings are simply a general 
response to caloric intake, as all mice in the present study maintained approximately the same 
amount of weight throughout the duration of the study, an important consideration given the 
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modulatory role of this system in food intake and body weight (Cansell et al, 2012; Shimizu et 
al, 2007).  
 The lack of effect on drinking behavior and ethanol metabolism is particularly interesting 
in light of changes in the expression of key melanocortin peptides following the last binge-like 
drinking cycle. Binge-like ethanol intake, but not sucrose intake, significantly blunted the 
expression of α-melanocyte stimulating hormone (α-MSH), the endogenous melanocortin agonist 
released from pro-opiomelanocrortin (POMC) neurons, in a number of hypothalamic nuclei. 
Further, an increase in the expression of agouti-related protein (AgRP), which functionally 
antagonizes α-MSH signaling at the melanocortin receptor, was detected in the paraventricular 
nucleus of the hypothalamus (PVN).  Importantly, these alterations were tightly restricted to 
regions of the hypothalamus, a brain structure with known involvement in both feeding-related 
(Anand et al, 1951; Fan et al, 1997) and reward-related (Marchant et al, 2012) behaviors, as 
extra-hypothalamic areas expressing these peptides did not show changes following ethanol (or 
sucrose) exposure. In general, these data confirm and expand upon previous observations 
indicating that ethanol exposure can decrease α-MSH immunoreactivity (IR) (Navarro et al, 
2008) or augment AgRP IR (Cubero et al, 2010). Importantly, the present findings extend 
previous work by utilizing a protocol of voluntary binge-like ethanol consumption (thus, not 
experimenter administered) that was not tied to caloric need, as is the case with a chronic 
ethanol-containing diet (Navarro et al, 2008). Further, these data highlight that while 
melanocortin signaling within many subregions of the hypothalamus are affected by ethanol 
intake, the lateral hypothalamus (LH) appears particularly sensitive to these effects, as just one 
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cycle of binge-like ethanol intake was sufficient to induce a downregulation of α-MSH IR within 
this region.  
 We also showed not only that binge-like ethanol drinking significantly alters the 
composition of the melanocortin system, but also that pharmacological manipulation of 
melanocortin receptors within the LH is sufficient to modulate excessive ethanol intake. Indeed, 
while intra-LH administration of the nonselective melanocortin agonist MTII blunted ethanol 
intake (but did not affect water or sucrose intake), intra-LH administration of the nonselective 
antagonist was sufficient to augment ethanol drinking; neither of these compounds affected 
excessive sucrose drinking. These data are in line with previous observations suggesting that 
MTII-induced blunting of ethanol consumption is receptor mediated (Navarro et al, 2003), and 
extend those data by indicating that MC4R within the LH are particularly important in the 
control of this behavior.  
 Interestingly, administration of a selective MC4R agonist significantly blunted both 
ethanol and sucrose drinking within the first half of the drinking session, and sucrose drinking 
over the entire session. These data are in line with previous work showing that ventricular 
administration of this MC4R agonist is sufficient to blunt ethanol intake in C57BL/6J mice 
(Navarro et al, 2005). Previous work has indicated that the effect of MTII on food (Kumar et al, 
2009) and ethanol (Navarro et al, 2005) intake are mediated by MC4R, not MC3R.  However, 
data have also shown that the MC3R is expressed on POMC neurons (Bagnol et al., 1999) where 
it is posited to act as an autoreceptor; this hypothesis is supported by the observation that 
agonism of the MC3R causes a downregulation of POMC mRNA in rats (Lee et al., 2008). 
Further, selective MC3R agonism stimulates food intake (Lee et al, 2008; Marks et al, 2006). 
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Together, these data suggest the possibility that a) MTII blunted ethanol consumption (and not 
sucrose consumption) due to the counteracting effect of MC3R activation selectively on sucrose 
consumption and b) administration of the MC4R agonist led to a decrease in both ethanol and 
sucrose intake because there was a lack of compensatory inhibition on sucrose intake due to a 
lack of agonism at the MC3R.  
 Finally, we showed that the blunting of excessive ethanol intake induced by intra-LH 
MTII agonism is at least partially mediated by ERK1/2 signaling in this region. Intra-LH 
administration of the MEK inhibitor U0126, which prevents the phosphorylation-dependent 
activation of ERK (London et al, 2008), did not have an effect on ethanol drinking. However 
pre-treatment with this compound prior to intra-LH infusions of MTII blunted the expected 
reduction in ethanol intake; these data resonate with the observations that inhibition of ERK 
signaling in the rat solitary nucleus blocked the MTII-induced suppression of feeding behavior 
(Sutton et al, 2005). Although mice that received pretreatment with the MEK inhibitor did not 
show significantly blunted ethanol intake relative to vehicle treated mice, they also did not 
display significantly elevated intake relative to MTII-treated animals that received vehicle, 
indicating that pretreatment with U0126 was unable to completely block the effect of MTII. 
These data suggest that while this behavior is likely mediated, at least in part, by other 
intracellular signaling mechanisms, ERK1/2 signaling plays a significant role in modulating this 
behavior (Figure 6.1).  
A Dysregulated System 
 The alterations in α-MSH and AgRP immunoreactivity (IR) observed following repeated 
exposure to ethanol are consistent with the hypothesis that excessive ethanol consumption leads 
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to a dysregulation of hypothalamic melanocortin signaling. Although there are a number of 
possible explanations for the decrease in hypothalamic α-MSH observed in the present 
investigation, the most attractive possibility given previous literature suggests that exposure to 
excessive levels of voluntarily consumed ethanol leads to a disruption in normal α-MSH 
signaling as a result of inhibition of normal α-MSH synthesis. A number of previous 
observations support this hypothesis. First, in a protocol designed to simulate a pattern of chronic 
ethanol exposure and withdrawal similar to that experienced by human alcoholics, chronic 
ethanol was associated with a significant decrease in POMC mRNA (Rasmussen et al, 2002); as 
α-MSH is cleaved from POMC, a decrease in POMC mRNA would be consistent with a 
decrease in α-MSH.  Recent evidence has also confirmed that chronic exposure to an ethanol-
containing diet leads to blunted POMC IR specifically in the arcuate nucleus of the 
hypothalamus (Navarro et al, 2013). Prolonged abstinence following chronic ethanol exposure 
has also been linked with an increase in POMC mRNA, suggesting that this polypeptide exhibits 
a remarkable ability to adapt to a changing environment (Rasmussen et al, 2002). However, it 
remains unclear whether ethanol is exerting a direct effect on POMC mRNA or whether this 
reduction is an indirect effect of ethanol acting upon other systems. For example, recent evidence 
indicates that exposure to alcohol may impact the expression of a subset of genes found in 
POMC-expressing neurons that are related to the circadian cycle; authors in that study postulated 
that early exposure to ethanol might lead to a lasting reduction in POMC functioning as a result 
of effects on these metabolism-regulating genes within the hypothalamus (Agapito et al, 2013). 
Further, several genetic models have provided evidence for a derangement of the 
melanocortin system in the control of alcohol consumption. Alcohol-preferring AA rats, 
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genetically bred for their natural inclination to prefer ethanol solutions  over water, show 
enhanced POMC mRNA in the hypothalamus relative to their non-drinking ANA counterparts 
(Gianoulakis et al, 1992). Additionally, these AA rats display not only a higher POMC/AgRP 
ratio in the arcuate nucleus of the hypothalamus relative to ANA rats, but also a perturbation of 
MC3R expression within this region (Lindblom et al, 2002b). These observations are not unique 
to AA/ANA rats: observations from a separate strain of high alcohol preferring (HAP) and low 
alcohol preferring (LAP) rats showed comparable results, with HAP rats displaying significantly 
elevated POMC mRNA in the ARC relative to the LAP rats (Kinoshita et al, 2004). Further, 
ethanol-drinking C57BL/6 mice display significantly elevated POMC mRNA in the 
hypothalamus relative to non-drinking DBA/2 mice (De Waele et al, 1992).  
These results may appear somewhat at odds with the decrease in α-MSH detected 
following binge-like ethanol exposure, as it may have been expected that ethanol-preferring 
rodents would display lower, not higher, levels of POMC mRNA. It is important to note that 
POMC can be cleaved into a number of derivatives that have been implicated in modulating 
neurobiological responses to ethanol, including adrenocorticoptropin hormone (ACTH) and β-
endorphin; thus an increase in POMC expression may not directly indicate an increase in α-MSH 
expression. Additionally, it is interesting to speculate that a decrease in α-MSH signaling 
following ethanol consumption in AA rats may serve to bring the α-MSH/AgRP ratio back to the 
“normal” levels observed in non-preferring rats. These observations, along with a growing 
literature showing that melanocortin agonism blunts ethanol intake (Rainero et al, 1990) and 
administration of exogenous AgRP increases ethanol intake (Navarro et al, 2005), as well as that 
genetic deletion of AgRP attenuates binge-like ethanol intake (Navarro et al, 2009), may suggest 
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that under normal conditions, stimulation of melanocortin receptors is protective against ethanol 
intake. Following repeated cycles of excessive ethanol consumption, however, a decrease in α-
MSH expression may tip the established α-MSH/AgRP ratio in such a way that these protective 
effects are disrupted. Once this system is sufficiently dysregulated, further uncontrolled and 
excessive ethanol drinking may ensue.    
Lasting Changes 
The present studies examined the expression of α-MSH and AgRP following repeated 
cycles of ethanol exposure, although the expression of melanocortin receptors within this region 
was not determined due to a lack of available good antibodies. Previous work has described 
alterations in MC4R, but not MC3R, density as a result of dietary changes. Food-restricted rats, 
potentially as a secondary effect of decreased α-MSH secretion, display an upregulation of 
MC4R, particularly in the dorosomedial (DMH), arcuate (ARC) and ventromedial (VMH) nuclei 
of the hypothalamus (Harrold et al, 1999). Further, a downregulation of this receptor was 
observed under conditions of diet-induced obesity, suggesting that an increase in α-MSH may be 
an attempt to limit continued overeating. As POMC neurons thus appear to sense and respond to 
both positive and negative changes in energy balance, indicated by these data from restricted and 
obese rats, it would be of interest to examine if excessive levels of voluntary ethanol exposure 
would be sufficient to augment receptor distribution as well. It has already been shown that AA 
and ANA rats, which differ in their inclination to drink or avoid ethanol, display divergent 
expression patterns of melanocortin receptors, particularly in the arcuate nucleus (Lindblom et 
al, 2002b). Given the decrease in LH α-MSH detected after one cycle of DID, it may be expected 
that this region would show a compensatory increase in MC4R, but not MC3R, expression, given 
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that the MC4R in particular has been linked with ethanol-intake behaviors (Navarro et al, 2005). 
With longer durations of ethanol experience, α-MSH expression was shown to decrease in other 
regions of the hypothalamus, possibly as a result of the continuing depletion of α-MSH stores; 
thus it may be expected that as the amount of ethanol experience increases, the upregulation of 
MC4R may also spread. 
In the present study, the expression patterns of α-MSH and AgRP were examined 
immediately after bottles were removed following the final binge test. As long-term abstinence 
following a chronic ethanol diet has been linked with an overall upregulation of POMC mRNA 
(Rasmussen et al, 1998), it will be important for future studies to examine the duration of 
observed changes in α-MSH and AgRP as related to ethanol history. In line with the allostasis 
model, which has previously been described as a mechanism by which ethanol dependence may 
develop (Koob, 2003; Lowery-Gionta et al, 2012), it may be expected that this decrease in α-
MSH may initially be a transient phenomenon, lasting only a short while following ethanol 
presentation. However, with repeated cycles of binge-like ethanol drinking, this downregulation 
may become more rigid as the general level of α-MSH expression reaches a new, lower, 
homeostatic set point.  Following repeated cycles of binge-like drinking, this downregulation of 
α-MSH may be evident for days, if not longer. Thus a persistent dysregulation of α-MSH 
signaling may be a contributory factor in the development of a dependent state, though future 
research will be necessary to confirm this hypothesis. 
Melanocortins and the Lateral Hypothalamus 
Interestingly, alterations in α-MSH expression within the LH appeared following just one 
cycle of binge-like ethanol intake, suggesting that this region is particularly susceptible to 
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ethanol-induced melanocortin signaling dysregulation. Alterations appeared in other 
hypothalamic regions following a somewhat longer ethanol history (DMH, 3 cycles; ARC and 
PVN, 6 cycles). While the ARC is one of the major sites of POMC biosynthesis (Madeira and 
Paula-Barbosa, 1999), POMC neurons have been shown to innervate a number of other regions, 
with the densest projections innervating the PVN and DMH. Indeed, the ARC has long been 
implicated as a region vital for the integration of circulating energy signals: within this region, 
the adipostatic hormones leptin and insulin contribute to the regulation of energy homeostasis via 
inhibition of AgRP-expressing neurons and excitation of POMC-expressing expressing neurons 
(Cone, 2005; Nahon, 2006). These alterations are thought to impact signaling between the 
arcuate and the PVN, a region ultimately in control of food intake. In support of this hypothesis, 
the PVN has been indicated as a primary region in which MC4R controls food intake, as 
selective MC4R agonism or antagonism within this region leads to a lasting decrease or increase, 
respectively, of food intake (Giraudo et al, 1998).  
The LH is well-established as an integrator of both metabolic and environmental stimuli; 
while MC4R are expressed in this region (Kishi et al, 2003), the role of the MC4R in the LH in 
mediating these behaviors is not completely understood. A recent investigation utilized mice in 
which green fluorescent protein (GFP) was under the control of the MC4R gene promoter 
(MC4R-GFP) in order to explore the anatomical distribution of this receptor, particularly in the 
LH (Cui et al, 2012). Here, it was observed that MC4R-GFP neurons were co-expressed with 
both neurotensin and the leptin receptor (LepRb).  Pharmacological evidence from this study also 
indicated that these MC4R-GFP-expressing neurons in the LH may interact with other LH 
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neurons, such as orexin, via local circuitry, as peripheral MTII administration induced c-Fos 
expression in LH orexin neurons (Cui et al, 2012). 
Given the role of the LH in both appetitive mechanisms and in mechanisms that modulate 
the reinforcing properties of natural rewards and drugs of abuse (Marchant et al, 2009), it is 
tempting to speculate that the particular sensitivity of the melanocortin system in this region to 
excessive voluntary ethanol intake relates, at least in part, to the modulation of the rewarding 
properties of ethanol. In the present work, intra-LH MTII blunted ethanol intake, but not sucrose 
or water intake; AgRP was similarly ineffective at affecting sucrose intake. Interestingly, 
selective agonism of MC4R was sufficient to blunt both ethanol and sucrose intake (see above), 
and previous work has indicated that i.c.v. administration of MTII modulates the ingestion of 
salient reinforcers (ethanol, sucrose, and saccharin) regardless of caloric content (Navarro et al, 
2011). Thus future work will be necessary to further probe the mechanism by which 
melanocortin signaling in this region, as well as other regions of the hypothalamus, modulates 
binge-like ethanol consumption. In particular, it will be interesting to determine whether agonism 
of melanocortin signaling in the ARC or PVN would blunt excessive ethanol consumption, and if 
so, whether this effect would retain specificity to ethanol consumption or would generalize to all 
consummatory behavior. 
Multiple Receptors and Divergent Pathways 
As noted above, melanocortin agonism blunted binge-like ethanol intake, while 
antagonism augmented this drinking behavior. Further, this effect appeared to be mediated by the 
MC4R, data that fall in line with previous work indicating an important role of this receptor in 
mediating feeding behavior and ethanol intake. Surprisingly, while agonism at MC3R and MC4R 
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simultaneously (via administration of the potent nonselective melanocortin agonist MTII) 
selectively blunted  ethanol intake without influencing sucrose drinking, selective MC4R 
agonism blunted both ethanol and sucrose intake. These observations indicate that the MC3R 
may play a particularly important role in modulating sucrose drinking: that is, while MC3R 
agonism appeared to counteract the effects of MC4R agonism on sucrose drinking when MTII 
was administered, MC4R agonism alone was sufficient to attenuate sucrose drinking. If is of 
interest to consider the potential roles of the MC3R and MC4R in modulating binge-like ethanol 
drinking in light of the high level of expression of these receptors in the brain. It is possible that 
the melanocortin-modulated effects on ethanol drinking behavior may be controlled in part by 
activity of the MC3R as an autoreceptor on POMC neurons (Bagnol et al, 1999; Lee et al, 2008). 
Although there has been limited examination of this receptor in the modulation of ethanol intake, 
MC3R
-/-
 mice show a blunting of voluntary ethanol intake in response to MTII administration 
(Navarro et al, 2005), suggesting that the MC3R is not critically involved in this behavior. 
However, recent observations from our laboratory have also suggested that mice lacking normal 
MC3R expression are more susceptible to the effects of MTII on excessive binge-like ethanol 
intake relative to their wild-type counterparts, further suggesting the possibility that MC3R may 
act as a presynaptic inhibitory autoreceptor on POMC neurons or as a postsynaptic receptor that 
functionally opposes the downstream actions of the MC4R (unpublished observations, J.J. Olney 
2013). Thus future studies are needed to examine the roles of the MC3R and MC4R separately 
and in combination in regards to the modulation of ethanol intake.  
Finally, previous work suggests that divergent neural pathways may modulate 
low/moderate ethanol drinking versus excessive binge-like ethanol drinking. For example, the 
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neuropeptide Y (NPY) and corticotrophin-releasing factor (CRF) systems have repeatedly been 
implicated as having complementary roles in specifically modulating excessive (“binge-like”) 
levels of consumption prior to the development of ethanol dependence, without participating in 
the control of moderate, non-binge-like ethanol intake (Lowery-Gionta et al, 2012; Sparrow et 
al, 2012). While the present data suggest a central role of melanocortin signaling in modulating 
binge-like ethanol consumption, previous reports have indicated that this system is also involved 
in moderate levels of ethanol intake characteristic of 24-h access two-bottle voluntary 
consumption procedures (Navarro et al, 2003). This observation is particularly intriguing in light 
of a growing body of literature supporting overlapping neural mechanisms underlying obesity 
and alcoholism. The melanocortin system has a well-characterized involvement in modulating 
food intake and energy homeostasis, and recent observations (including those discussed in the 
present dissertation) indicate that this system plays an important role in modulating 
neurobiological responses to ethanol intake, particularly excessive ethanol intake. Thus an 
interesting possibility is that while low to moderate levels of ethanol consumption engage the 
melanocortin system in a capacity similar to that of natural rewards (i.e., palatable food), 
repeated episodes of excessive levels of consumption lead to a rigid dysregulation of normal 
melanocortin functioning, thereby perpetuating further excessive ethanol consumption and 
ultimately to dependence. 
Overlapping Neural Mechanisms 
 A growing literature supports the idea that (partially) overlapping neural mechanisms 
underlie dysregulated eating behavior and alcohol use disorders. Ethanol is a somewhat unique 
drug of abuse, as it not only possesses psychoactive qualities that make it an attractive substance 
115 
 
for potential abuse, but also possesses calories and is thus a potential source of nutrients. While 
ethanol does not provide nutrients that would allow for sustained ethanol consumption in lieu of 
food, it is possible that the rewarding properties of ethanol may tap into reward pathways that 
naturally respond to food, particularly that of the palatable variety. In support of this theory, 
numerous reports have indicated that eating disorders are highly comorbid with alcohol use 
disorders in the community population (Dansky et al, 2000; Holderness et al, 1994) even 
indicating that the prevalence of alcohol use disorders in patients suffering from bulimia nervosa 
may exceed 50%. Case reports, although limited in their scope, have also indicated that co-
treatment of both disorders at the same time may be efficacious in some patients (Daniels et al, 
1999; Dawe and Staiger, 1998) 
 However, there is still a great debate as to a) the nature of the overlap between disordered 
eating and addiction and b) whether this overlap is sufficient to declare that food itself can truly 
be addicting. There is some thought that “food addiction” is more of a phenotypic descriptor 
without a solid neurobiological basis than a certifiable disorder (Ziauddeen and Fletcher, 2013). 
Indeed, while electrophysiological recordings have shown that natural reinforces and drugs of 
abuse both elicit cell firing in the nucleus accumbens, there is evidence that these events may 
occur through separate circuits (Carelli et al, 2000). The most convincing evidence that food can 
elicit addictive-like behaviors has come from animal literature, whereby animals exposed to diets 
high in fat and/or sugar displayed behaviors characteristic of addiction, including compulsive 
food seeking and withdrawal (Avena et al, 2008; Johnson and Kenny, 2010). To date, human 
neuroscience literature has been somewhat mixed, although an interesting study examining 
individuals who scored either high or low on the Yale Food Addiction Scale (YFAS) indicated 
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that individuals with high YFAS scores were more responsive to substance-related cutes than 
low-scoring individuals, data in line with the incentive salience theory of addiction (Gearhardt et 
al, 2011; Robinson and Berridge, 1993). In general, human neuroscience literature has remained 
inconclusive as to whether or not “food addiction” should be classified as an addiction alongside 
the likes of alcoholism (Ziauddeen et al, 2013) . Clearly, further work is needed to probe the 
underlying neural circuitry at play in these disorders. 
 Despite the ongoing debate as to whether “food addiction” can be classified the same 
manner as drug addiction, it is interesting to consider the data presented in the current 
dissertation in the context of work suggesting the possibility that partially overlapping neural 
mechanisms may underlie both eating disorders (including obesity) and alcoholism (Volkow et 
al, 2013b). That is, it is possible that the melanocortin system is a key component linking the 
regulation of energy homeostasis and feeding behavior with the natural reward system of the 
brain, and that the derangement of normal melanocortin signaling may lead to an addicted 
phenotype.  One observation that may support the role of this system as a participant in such 
overlapping pathways harkens back to the observation that the same endogenous agonist, α-
MSH, activates all five melanocortin receptors (see Chapter 1: Introduction), which participate 
in a diverse array of processes.  
 One of the possible ways that this melanocortin agonist influences such a variety of 
disparate behaviors may lie in the activation of divergent intracellular signaling mechanisms.  As 
discussed in Chapter 4, it would appear that melanocortin signaling may exert its actions via 
ERK signaling, which may or may not be independent of the cAMP-PKA pathway (Figure 6.1). 
Indeed, an abundance of work has indicated that the MC4R, as a Gs-linked G-protein coupled 
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receptor, signals through the cAMP-PKA pathway (Gantz et al, 1993; Mul et al, 2012) and that 
MC4R-induced activation of this pathway can influence the expression of a number of genes, 
including BDNF (Caruso et al, 2012). However, other literature has indicated that behaviors 
induced via MC4R signaling may rely to a greater extent on the activation of ERK1/2 signaling 
(Sutton et al, 2005). Although cAMP-PKA signaling may lead to the phosphorylation of MEK 
and thus activation of ERK1/2 signaling directly, there is also evidence suggesting that this 
process may occur at least somewhat independently of PKA (Daniels et al, 2003; Sutton et al, 
2005), and may even require PKC activity instead (Chai et al, 2006). Other suggested 
mechanisms for PKA-independent ERK1/2 activation include a cAMP-responsive guanidine 
nucleotide exchange factor (de Rooij et al, 1998) and a Gi-protein-PI3K signaling mechanism 
(Chai et al, 2007).  Thus exactly which pathways are initiated following MC4R agonism in the 
LH, as well as the relative importance of each of these pathways, remain uncertain. Indeed, at 
this point it is unclear whether melanocortin-induced activation of PKA and ERK1/2 are part of 
one convoluted pathway or are part of parallel pathways (Breit et al, 2011).  
The understanding of the intracellular mechanisms initiated by MC4R, however, may 
help explain the long-lasting effect of MTII-induced agonism on both food (Fan et al, 1997) and 
ethanol (Thiele et al, 1998) intake, particularly in light of the relatively short half-life of this drug 
(Ugwu et al, 1994). The present data indicated that MTII may specifically modulate excessive 
ethanol intake via engagement of the ERK1/2 signaling pathway, an intracellular mechanism that 
has previously been shown to directly modulate gene expression via phosphorylation of a 
number of transcription factors (Impey et al, 1999). To date, melanocortin receptor signaling has 
been shown to impact the expression of a number of genes linked with neurobiological responses 
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to ethanol, including BDNF (Davis, 2008; Xu et al, 2003; Zanardini et al, 2011) and CRF 
(Fekete et al, 2000; Lowery-Gionta et al, 2012). 
Melanocortin Signaling and Orexin 
Perhaps the most attractive mechanism for the long-lasting effects of melanocortin 
agonism on ethanol intake, particularly in light of the present data, lies with orexin. Orexin has 
previously been associated with a number of reward processing, drug abuse, and alcohol seeking 
behaviors (DiLeone et al, 2003; Harris et al, 2005; Lawrence et al, 2006). Further, central 
administration of α-MSH has previously been shown to decrease orexin mRNA (Hanada et al, 
2000), and intra-LH injections of orexin in Sprague-Dawley rats have been shown to selectively 
stimulate voluntary ethanol consumption without affecting food or water consumption 
(Schneider et al, 2007). 
 In the present report, we found a significant blunting of α-MSH in the LH following one 
cycle of binge-like ethanol drinking, an effect that persisted in mice that experienced multiple 
cycles of excessive alcohol consumption. If melanocortin agonism (endogenously, via α-MSH) 
can blunt orexin signaling, it is thus plausible that a blunting of α-MSH signaling may result in 
an increase in orexin activity, thereby promoting further ethanol intake. Recent data failed to find 
MC4R on orexin neurons in the LH, although MC4Rs were detected on LH neurons expressing 
either the neuropeptide neurotensin or long form of the leptin receptor (LepRb) (Cui et al, 2012). 
Pharmacological data from this study also indicated that MC4R may interact with orexin via 
local circuitry.  
These data are interesting in light of previous work indicating that LH LepRb-expressing 
neurons synapse onto orexin neurons in the LH (Louis et al, 2010). Further, intra-LH infusion of 
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leptin has been shown to dramatically increase LH orexin mRNA, but not LH MCH mRNA, 
indicating that leptin action via LepRb neurons in the LH specifically modulates orexin gene 
expression in this region. A separate study has indicated that a majority of leptin-responsive 
LepRb neurons in the LH also express neurotensin (LepRb
Nts
) (Leinninger et al, 2011). These 
LepRb
Nts
 neurons were shown to decrease orexin expression and the activity of orexin neurons, 
likely through GABA-mediated inhibition. Thus it is interesting to speculate that α-MSH 
activation of MC4R may lead to a decrease in ethanol intake due to an inhibition of orexin 
signaling via LepRb (or perhaps LepRb
Nts
) neurons (Figure 6.2) in the LH. Further, blunted α-
MSH signaling, as observed following binge-like ethanol intake, may thus lead to an increase in 
orexin activity due to a decrease in orexin inhibition mediated by these LepRb (or LepRb
Nts
) 
neurons. Together, these data suggest that the interaction between the melanocortin and orexin 
systems may be an attractive target for investigation as a nexus whereby mechanisms underlying 
food and ethanol consumption may interact. Thus future work is clearly needed to probe the 
nature of this relationship and determine exactly how MC4R agonism may modulate orexin 
signaling within the LH. 
Future Directions 
 The results of the current dissertation have provided insight into the role of the 
melanocortin system in modulating excessive “binge-like” ethanol drinking in C57BL/6J mice. 
In particular, these results have indicated that melanocortin signaling within the lateral 
hypothalamus may play an important role in mediating this pattern of behavior. However, these 
intriguing data have also opened the door to a number of future studies that will be needed to 
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further examine the relationships between ethanol, the melanocortin system, and potential 
downstream effectors as they relate to the perseverance of excessive ethanol consumption.  
For example, follow-up investigations are needed to examine whether ethanol directly 
affects the expression of α-MSH, or if this effect is mediated by a separate system. Further, 
follow-up studies are needed to examine the nature of the potential relationship between 
endogenous melanocortin and orexin signaling, to determine if it is plausible that an interaction 
between these networks may indeed play a critical role in the overlapping pathways underlying 
natural and drug reward. Further, it will be important to examine the duration of the effects 
observed in the present dissertation. For example, are the alterations in melanocortin peptides 
following excessive ethanol exposure long-lasting to the extent that they may help explain the 
persistence of binge-like drinking that may lead to dependence, as observed in the human 
population? And is repeated withdrawal from such excessive levels of drinking an essential 
component of this process? While we have found that binge-like ethanol drinking and binge-like 
exposure to ethanol (Navarro et al., 2008, 2013) causes a down-regulation of α-MSH and POMC 
IR, it will also be important to determine if binge-like ethanol drinking is associated with a 
down-regulation of POMC mRNA, and changes in melanocortin receptors and AgRP mRNA to 
gain a more broad understanding if how ethanol influences this system. Future experiments will 
also be necessary to examine the role of other hypothalamic regions on modulating this behavior. 
For example, while the lateral hypothalamus has clearly been indicated as playing a particularly 
important role, do other regions of the hypothalamus with a robust melanocortin presence (i.e., 
the arcuate and paraventricular nuclei of the hypothalamus) also play a key role in modulating 
excessive ethanol intake, or is their role limited to that of modulating natural reward? Finally, 
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particularly if manipulation of the melanocortin system proves to be an attractive target for 
pharmacological treatments aimed at the treatment of alcohol use disorders in the human 
population, it will be important to more clearly understand the role of different melanocortin 
receptors (specifically, MC3R vs. MC4R) in modulating these behaviors. In the end, future 
investigation into the role of the melanocortin system – and the systems with which it interacts – 
may prove extremely beneficial in understanding the complex neurocircuitry that may underlie 
multiple types of addictive behavior, including alcoholism.  
 
.  
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Figure 6.1: Schematic depicting intracellular signaling mechanisms activated by α-MSH 
agonism of the MC4R in the LH. POMC neurons, which release the endogenous melanocortin 
agonist α-MSH, originate from the arcuate nucleus of the hypothalamus and project to the lateral 
hypothalamus. Here, they activate the Gs-coupled MC4R, which acts via a number of 
intracellular signaling mechanisms. While agonism of the MC4R may activate ERK1/2 signaling 
via the cAMP-PKA pathway, evidence has also suggested that ERK1/2 may be activated via 
PKA-independent means, as well. Research from the present dissertation suggests that ERK1/2 
signaling is important for the modulation of binge-like drinking behavior, but also indicates that 
separate mechanisms may be involved as well. 
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Figure 6.2: Schematic depicting the potential interaction between the melanocortin and orexin 
systems in the LH. Data from the present dissertation indicate that melanocortin signaling 
through MC4R in the LH modulates binge-like ethanol drinking. POMC neurons from the 
arcuate nucleus of the hypothalamus project to the lateral hypothalamus, where previous work 
has indicated that MC4R are expressed on LepRb neurons. Further, LepRb neurons, and LepRb 
neurons expressing neurotensin (LepRb
NTS
) in the LH have been shown to modulate local orexin 
activity via GABAergic inhibition. Thus we propose that melanocortin signaling through MC4R 
in the LH acts via a local circuit, possibly involving LepRb or LepRb
NTS 
neurons, to modulate 
orexin activity within the LH. Orexin neurons, particularly through projections to regions of the 
mesolimbic dopaminergic system including the ventral tegmental area (VTA) may then modulate 
binge-like ethanol intake. 
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